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Pencil beam scanning (PBS) is a specialized form of proton therapy that utilizes inverse 
planning in conjunction with intensity modulation of proton beam spots for treatment delivery. 
In recent years, PBS has seen widespread adoption among the proton therapy community and 
most newly constructed proton therapy facilities utilize this modality. Due to the widespread 
adoption of PBS, there has been considerable effort by commercial and institutional entities to 
improve the efficacy of this form of proton therapy. Although there have been numerous 
advancements in the clinical use of PBS, many improvements are ongoing or have yet to be 
implemented clinically.  
The purpose of this doctoral thesis is to explore clinically relevant improvements and 
technological advancements for PBS treatments. The work presented in this thesis first 
highlights recent technological advancements that are aimed at improving the quality of PBS 
delivery for the treatment of cancer. Next, multiple novel clinical translational research projects 
carried out at the Seattle Cancer Care Alliance Proton Therapy Center (SCCAPTC) will be 
presented. The aim of this work is to explore various approaches to improve and advance the 
efficacy of PBS for the treatment of cancer. The numerous strategies for improving PBS 
delivery presented in this work can be divided into two general categories: (1) delivery 
strategies and (2) computational methods.  
The first topic dealing with delivery strategies for PBS describes the validation and clinical 
implementation of aperture collimators for PBS as a delivery method to sharpen lateral 
penumbra. Reduction of lateral penumbra for PBS improves dose conformality and enables 
enhanced dosimetric sparing of critical organs at risk adjacent to the treatment target. Next, 
work carried out for validation and clinical implementation of chair-based PBS treatments 
using a commercial treatment planning system is presented. Treatment in the seated position 
can aid particle therapy centers with fixed beamlines by allowing more flexibility in patient 
positioning/orientation thus facilitating an increased number of available beam angles available 
for treatment.   
On the topic of advancing computational methods for PBS delivery, this work first investigates 
comparisons between analytical and Monte Carlo dose calculation algorithms for the treatment 
of lung cancer. This work highlights the importance of utilizing Monte Carlo dose calculation 




characterizes the delivery error of PBS treatments through analysis of irradiation log-files. Data 
extracted from irradiation log files was then used to develop a computational framework for 
delivery error prediction within a commercial treatment planning system using machine 
learning. 
In presenting highly relevant clinical research, the overall aim of this doctoral thesis is to 
disseminate these technological advancements with the hope that they can be translated into 
clinical use among the broader proton therapy community and contribute to the improvement 






CHAPTER 1: INTRODUCTION 
1.1 Overview 
The use of high energy protons for the treatment of cancer was first proposed by Dr. Robert 
Wilson in 1946 (1). Almost a decade later, some of the first patients to receive proton therapy 
were treated at the Berkley Radiation Laboratory in 1954 (2). For the next several decades, use 
of proton therapy was limited to research laboratories including Los Alamos National 
Laboratory and Harvard University. The first hospital-based proton therapy center was the 
Loma Linda University Proton Therapy Center in California and was established in 1988 
following approval of proton therapy by the U.S. Food and Drug Administration (2). Over the 
next two decades, many additional hospital-based proton therapy centers were established with 
Massachusetts General Hospital, MD Anderson Proton Center and the Midwest Proton 
Therapy Institute being among the early developments.  
More recently, PBS has gained widespread use and has become the standard of care among 
most modern proton therapy facilities. PBS, also known as spot scanning, was first 
implemented clinically at the Paul Scherrer Institute in Switzerland (PSI) in 1990 (3). Unlike 
proton therapy delivery techniques such as double scattering (DS) and uniform scanning (US) 
(4, 5), PBS does not require the use of beamline scattering devices for field modulation or 
patient-specific apertures/compensators for beam shaping. Instead, in PBS delivery, scanning 
magnets are used to steer the proton beam and irradiate beam spots across the tumor volume as 
shown in Figure 1.1.  
 
 
Figure 1.1. Diagram of a proton PBS nozzle irradiating a target. Image taken from Hall (6).  
PBS beam spots are delivered in layers with each layer corresponding to a specific energy. 
Furthermore, the intensity of each beam spot can be varied allowing for superior dose 




PBS by many new and future clinics has been a major technological advancement for proton 
beam therapy. 
Despite the advantages of PBS over other proton therapy modalities such as US and DS, there 
remain numerous improvements to be made that can positively impact the quality and accuracy 
of PBS delivery for patient treatments. Development and improvement of PBS technology is 
an active area of research and many studies have been published on this topic since PBS was 
first implemented clinically at PSI. The research in this doctoral thesis will focus on 
technological advancements and contribute novel studies to the existing literature.  
 
1.2 Aims/Chapter Outlines 
Aim 1: Investigation and implementation of aperture collimators for PBS 
Chapter 3 explores the utilization of aperture collimators for PBS treatments. This chapter 
begins by characterizing the lateral falloff of PBS beams with and without use of an aperture 
as a function of various beam parameters. This chapter aims to provide clinical guidance to the 
broader proton therapy community regarding use of apertures for PBS by characterizing 
aperture-collimated PBS penumbra as a function of various beam characteristics. Finally, this 
chapter will describe commissioning and validation of aperture collimators for PBS treatments 
using a commercial treatment planning system (TPS).  
Aim 2: Clinical validation of PBS treatments in the seated position 
Chapter 4 presents the clinical validation and implementation of a chair in a commercial TPS 
for PBS treatments with the patient in the seated position. Treatment in the seated position 
addresses the limitation of available beam angles when treating in a fixed proton beamline. The 
goal of this chapter is then to present the commissioning and clinical implementation of 
treatments in the seated position within a commercial TPS. This work can serve as a basis for 
implementation of chair-based treatments which is a useful topic for proton therapy clinics that 
are faced with the beam angle limitations of a fixed beamline.  
Aim 3: Comparisons of PB and MC dose calculation in lung 
Chapter 5 first reviews the performance and accuracy of pencil beam (PB) and Monte Carlo 
(MC) dose calculation algorithms for PBS as implemented in a commercial TPS. This chapter 




highly heterogeneous media. Next, differences in PBS dose distributions between PB and MC 
calculated treatment plans for a cohort of lung cancer patients was investigated. This was 
carried out through a comparative dosimetric analysis between commercial implementations 
of MC and PB dose engines performed on these ten patient plans. The aim of this chapter is to 
highlight the importance of using MC dose calculation for the treatment of lung cancer.  
Aim 4: Application of machine learning for prediction of PBS delivery error 
Chapter 6 investigates the novel use of machine learning (ML) models for delivery error 
prediction in PBS delivery. The work in this chapter utilized irradiation log-files which contain 
delivered spot parameters including spot position and MU for PBS fields following beam 
delivery. Delivered spot parameters from the log-files were first compared to the planned 
parameters extracted from the TPS for a set of previously-treated prostate patients. 
Characterization of spot position and MU delivery error was carried out as well as the 
dosimetric impact of this delivery error on a test prostate patient. Next, this dataset of planned 
parameters from the TPS and delivered parameters from the log-files was used as a training 
dataset for three ML models which were trained to predict delivered spot parameters based on 
planned parameters. Of the three ML models that were tested in this study, it was concluded 
that the random forest regression model performed the best in prediction of delivered spot 
parameters compared to linear regression and neural network model. The main objective of this 
chapter is to demonstrate to the reader that (1) delivery errors in PBS beams can impact 
treatment plans and (2) ML models can be trained to predict this delivery error.  
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CHAPTER 2: LITERATURE REVIEW 
2.1 Use of aperture collimators for PBS 
 
Proton PBS allows for highly conformal treatment deliveries, minimizing dose to surrounding 
tissue (11, 12). This is accomplished by careful placement of spots tightly around the target 
volume in a way that limits dose to healthy tissue (12). Other proton beam delivery techniques 
such as DS utilize aperture collimation for field shaping which results in sharper lateral 
penumbra than PBS without apertures. Recently, the Raystation TPS (Raysearch Laboratories, 
Stockholm, Sweden) has coupled the strengths of each delivery technique by adding the 
application of apertures to PBS fields (11, 13, 14). While PBS delivery has traditionally been 
delivered without the application of apertures, the use of aperture collimation can reduce lateral 
penumbra and, therefore, minimize dose to critical organs at risk for certain disease sites (15).  
Various studies have been conducted investigating the use of apertures in PBS beam delivery. 
One of the first studies dealing with the collimation of PBS beams for reduction of lateral 
penumbra was presented by Bues et al. (16). In this study a proton multi-leaf collimator (MLC) 
was modeled using the MCNPX MC code and the lateral penumbra (80%-20% distance) of 
PBS beams was analyzed with and without MLC collimation. This study showed a proton MLC 
can sharpen the lateral penumbra of a PBS beam up to 1cm for shallow depths as seen in the 
figure below (16). 
 
Figure 2.1. Plot showing penumbra of an un-collimated and MLC-collimated proton beam where the x and y 
axis are penumbra width (80%-20% distance in cm) and proton beam range respectively. Image taken from 





At deeper depths however, the lateral penumbra for a collimated PBS beam can exceed that of 
an un-collimated beam as shown in Figure 2.1 (16). 
In another study by Safai et al., analytical formulas were presented to describe the lateral 
penumbra between a collimated DS beam and un-collimated PBS beam using various 
collimator-to-surface distances, proton ranges and PBS spot sizes (17). These formulas were 
validated against profile measurements using an ionization chamber and were found to have an 
accuracy of 3% for depths larger than 7.6 cm. Results from the analytic formulas and 
measurements indicate that the penumbra of a pencil beam at shallow depths is larger than the 
penumbra of a collimated DS beam, but better at larger depths as shown in Figure 2.2 (17).  
 
Figure 2.2. Plot comparing the penumbra of a DS and un-collimated PBS beam. Image taken from Safai, 
Bortfeld (17). 
It is therefore concluded by Safai et al. that aperture collimation should be considered for PBS 
delivery for shallow targets (17).  
Another study by Dowdell et al. analyzed the out-of-field dose of a DS proton beam compared 
to a collimated and un-collimated PBS beam using the GEANT4 MC toolkit (18). In this work, 
Dowdell et al. demonstrated that PBS has an overall lower out-of-field dose compared to DS 
across multiple depths. Furthermore, the out-of-field dose for a PBS beam can be reduced 





Figure 2.3. Out-field dose (left) and equivalent dose (right) for a DS beam (square), un-collimated PBS beam 
(circle) and collimated PBS beam (triangle) at a depth of 28.32 cm in water. Image taken from Dowdell, Clasie 
(18). 
Use of an aperture results in the creation of secondary neutrons generated during the interaction 
of the PBS beam spots and the aperture. However, even though secondary neutron fluence is 
increased when using an aperture, a collimated PBS beam still results in lower out-field-dose 
compared to an un-collimated PBS beam. This is primarily due to the removal of large angle 
scatter when an aperture is applied (18).  
More recently Charlwood et al. performed MC simulations of a PBS nozzle using the GEANT4 
application for tomographic emission code (GATE) (15). In this study, the lateral penumbra of 
collimated and un-collimated PBS beams was analyzed against several parameters which 
included nozzle-to-surface distance, vacuum window-to-surface distance and range shifter 
thickness. Figure 2.4 shows penumbra width as a function of depth for un-collimated (blue) 
and collimated (red) PBS beams without a range shifter (a) and with a range shifter (b) using a 





Figure 2.4. Plot of an un-collimated (blue) and collimated (red) PBS beam with and without range shifter for 
various energies. Image taken from Charlwood, Aitkenhead (15).  
This study found that adding collimation to a PBS beam can sharpen the lateral penumbra by 
2 – 4 mm depending on depth. Furthermore, the lateral penumbra of an un-collimated PBS 
beam is particularly sensitive to nozzle-to-surface distance as well as whether or not a range 
shifter is used (15).  
Another study by Winterhalter et al. characterized the lateral penumbra of PBS beams with and 
without aperture collimation using the tool for particle simulation (TOPAS) (19) MC toolkit 
(20). In this study three optimization techniques were implemented: edge-collimated uniformly 
weighted spots (collimation), pencil beam optimization of un-collimated pencil beams (edge-
enhancement) and the optimization of edge collimated pencil beams (collimated edge-
enhancement) (20). Using these three optimization techniques, the lateral penumbra of PBS 
beams was evaluated across different range shifter thicknesses and airgaps. Furthermore, this 
study analyzed the effect on lateral penumbra by placing the aperture upstream and downstream 
of the range shifter. The study by Winterhalter et al. concluded that the sharpest lateral 
penumbra can be achieved by using collimated edge enhancement combined with an aperture 
positioned upstream from the range shifter (20).  
Baumer et al. carried out a similar study to that of Winterhalter et al. and investigated the lateral 




shifter (21). Furthermore, the lateral penumbra of a collimated PBS beam was compared to that 
of a DS proton beam. DS and PBS treatment plans were generated using the Raystation TPS. 
The TPS-calculated penumbra values were also validated against measurements using a 
scintillation detector and ionization chamber. Finally, DS and collimated PBS treatment plans 
were generated on a clinical CT scan of a target located in an ocular orbit. Interestingly, the 
study by Baumer et al. differed with that of Winterhalter et al. and concluded that the lateral 
penumbra of a PBS beam is approximately 20% less when the aperture is positioned 
downstream from the range shifter (21). As mentioned by Baumer et al., differences in 
conclusions between these two studies can be attributed to multiple factors including differing 
beamline components as well as range of energies studied (21). Furthermore, based on phantom 
data, this study also concludes that the lateral penumbra of a collimated PBS beam is larger 
than for a DS proton beam.  
More recently, Grewal et al. reported on penumbra sharpening and scattering of the adaptive 
aperture (AA) as implemented with the Mevion S250i compact pencil beam scanning proton 
therapy system (22). In this work, field edges were analyzed with film and scintillation 
detectors to characterize beam penumbra as a function of energy, and airgap. Measurements 
were carried out in solid water at various depths with film and in air with the scintillation 
detector. Finally, the dosimetric effects on clinical treatment plans were evaluated with plans 
optimized using AA and open fields. The study concluded that compared to open fields, in-air 
penumbra was reduced by 30-60% when using AA for treatment planning. At treatment depth, 
measurements carried out with film showed 10 to 14 mm of penumbra reduction when using 
AA (22). Note that the Mevion PBS system as described in Grewal et al. has spot sigma values 
that range from 3.8 mm to 29.4 mm for proton spot energies of 227.15 MeV and 33.04 MeV 
respectively. This is due to a series of range modulators located in the nozzle which induce 
increasingly larger angle scattering at lower energies. Due to these relatively larger spot sizes 
at lower energies, use of use aperture collimation such as AA is particularly important for 
maintaining optimal dose conformality for PBS delivery using the Mevion system presented in 
this work.  
 
2.2 Chair-based treatments in radiotherapy 
Radiotherapy in the seated position has been an active area of investigation for many years and 




however, implementation of chair-based radiotherapy has become a very active area of research 
among particle therapy centers. Due the prohibitive cost of constructing a full rotational gantry 
for a particle therapy beamline, many proton and heavy ion centers have opted to construct one 
or more fixed beamlines. Although fixed beamlines are more compact and require less 
resources to construct, available beam angles for these types of treatment rooms are limited 
when patients are treated on a conventional treatment couch in the supine position. For this 
reason, utilization of a rotational treatment chair with the patient immobilized in the seated 
position allows for the availability of more beam angles when treating in a fixed proton and/or 
heavy ion beamline. 
Rahim et al. has presented a historical view of this subject and summarized many of the studies 
in Figure 2.5 shown below (23).  
 
Figure 2.5. Various publications reporting on radiotherapy treatment chair apparatuses from 1956 to 2017. 
Image modified from Rahim et al. (23). 
Many of the chairs shown in Figure 2.5 were designed for use with external beam photon 
therapy (24-32). 
Some of the motivations for treating in the seated position include improved patient comfort as 




demonstrated high reproducibility of patient positioning as well as increased comfort for lung 
cancer patients (31). In this study a novel treatment chair with design characteristics optimized 
for lung cancer treatments was fabricated to allow for patient immobilization in the seated 
position (see Figure 2.6).  
 
Figure 2.6. Custom-designed treatment chair for radiotherapy in the seated 
position. Image taken from Duisters, Beurskens (31). 
In this study a cohort of 10 lung cancer patients was utilized to study the comfort and 
reproducibility of patient positioning and immobilization. To study these quantities patients 
were simulated on a conventional simulator in the supine and seated positions multiple times. 
Patients were also asked which treatment position they felt was more comfortable. Results of 
this study indicate that setup reproducibility was within 1 cm in both the seated and supine 
positions. Regarding comfort, all 10 patients reported that the seated position was superior 
compared to the supine setup. More interestingly there was significant change in the measured 
lung volume across the patient cohort between the two patient positions with the seated position 
corresponding to larger average total lung volume (3914 cm3 seated vs. 3162 cm3 supine) (31). 
This increase in lung volume in the seated position also led to a decrease in the irradiated lung 
volume based on analysis of test plans created in a TPS utilizing 10 MV photons to deliver 30 
Gy with a LINAC (31) although it is unclear if this same effect would be observed in the case 
of proton therapy.  
As mentioned earlier, development of treatment chairs is also an active area of interest among 
particle therapy centers in which fixed beamlines are commonly utilized for treatment. In a 




fixed therapeutic particle beamlines (33). In this work, a chair was fabricated and mounted to 
a robotic 6DOF platform allowing for patient positioning at multiple orientations in the seated 
position. 
 
Figure 2.7. Patient in the seated position on a custom-made treatment chair on rails in front of a fixed particle 
therapy beamline. Image taken from Sheng, Sun (34). 
As part of this study Sheng et al. investigated the positional accuracy and stability of the 
treatment chair using a motion capture system. Analysis of the positional accuracy of the chair 
showed all relevant positional parameters well within acceptable limits and were similar in 
magnitude to a clinically validated in-room robotic treatment couch. The reported positional 
and rotational accuracy of the chair were ± 0.12 mm and ± 0.04° respectively (34).  
In another study Buchner et al. presented a robotic chair which was designed for a compact 
proton therapy system and allowed for patient treatments in three positions: (1) sitting, (2) 





Figure 2.8. Illustration of a robotic chair used for a compact proton therapy system. The chair allows for the 
patient to be sitting (a), reclining (b) and lying. Image taken from Buchner, Yan (35). 
The prototype chair presented in this study utilized pneumatic immobilization units which were 
placed around the patient’s waist and shoulders. To evaluate patient setup stability in the chair, 
Buchner et al. employed a group of human volunteers. Each of these volunteers were 
immobilized in the treatment chair and their motion was tracked using a surface guidance 
device to monitor positional and rotational movements over time. Figure 2.9 shows the stability 
of a test patient setup over time freely sitting and immobilized compared to a clinical setup 
tolerance of 1 mm (translational) 0.5° (rotational) (35). 
 
Figure 2.9. Positional and rotational movements of a single test patient immobilized in the treatment over a 500 
sec. interval while freely sitting (pink) and immobilized (blue) compared to clinical reference tolerance of 
1mm/0.5° (dotted line). The top row shoes translational movements along the patient right-left (ΔTx), superior-
inferior (ΔTx) and anterior-posterior (ΔTz) directions. The bottom row shows rotation displacements in pitch 
(ΔRx) roll (ΔRy) and yaw (ΔRz). Image taken from Buchner, Yan (35). 
Results of this study show that the treatment chair can achieve suitable setup accuracy for 
proton therapy treatments while allowing for a multitude of patient positions and orientations.  
 
2.3 Improvements in PBS dose calculation algorithms 
Incorporation of MC into treatment planning has been among the most significant 
advancements in proton therapy dose calculation. Multiple studies have been conducted 
demonstrating the superior dose calculation accuracy of MC compared to the analytical pencil 




been the standard of care in proton therapy dose calculation and until recently this was the only 
dose calculation algorithm implemented in commercial TPSs. Many modern PB dose engines 
are based on the works of Hong et al. (45) and Schaffner et al. (46) and offer fast and efficient 
dose calculation at the cost of reduced accuracy especially in the presence of complex 
heterogeneities.  
In PB, PBS beams are decomposed into multiple beamlets often referred to as pencil beams. 
Furthermore, PB dose engines typically approximate a medium as a series of infinite 
homogeneous slabs where each of these slabs takes on a composition equal to the material 
composition encountered along the central axis of each beamlet at a given depth (47). For this 
reason, PB dose engines can yield sufficient accuracy in a homogenous environment. However, 
in the presence of complex geometries or heterogeneous environments, these algorithms can 
yield substantial errors in dose calculation. Further errors can result from an inability of PB 
dose calculation to correctly model elastic Coulomb scattering as well as elastic and inelastic 
nuclear interactions (48).  
In contrast to PB, MC dose calculation uses individual particle tracking where the outcome of 
each particle interaction is determined by sampling probability density distributions (47). In 
commercial MC implementations, a clinical beam model will include accurate information 
about the phase space of particles at nozzle exit. After exiting the beamline, particles are 
transported through a patient CT scan and the deposited energy at any given point due to 
particle interactions is scored. This process continues across a sufficiently large number of 
particles such that the statistical uncertainty for dose in a voxel is adequate. The statistical 
uncertainty of deposited energy in a voxel is inversely proportional to the square root of the 
number of simulated primary particles. Therefore, MC dose calculation can be very accurate 
provided a sufficient number of simulated particles are transported. For this reason, MC is often 
considered the gold standard of dose calculation algorithms (38).  
Multiple studies have been carried out investigating differences between MC and PB. In 2012 
Paganetti presented a thorough review of range uncertainties in proton therapy using MC and 
PB (38). In this study, Paganetti compared dose distributions of a proton beam on a patient CT 
using MC and PB and noted differences observed especially in highly heterogeneous regions 





Figure 2.10. Proton dose distributions calculated with analytical PB (left) and MC (right). Image taken from 
Paganetti (38). 
As can be seen in Figure 2.10, noticeable differences between PB and MC can be observed 
where the proton beam traverses a path tangential to a bone tissue interface. This difference 
can be attributed to the inability of PB to accurately model multiple coulomb scattering in 
complex heterogonous geometries (38).  
In another study Yamashita et al. implemented a GEANT4 framework to compare MC and PB 
dose distributions for various disease sites (39). In this work treatment plans were generated 
with the XIO TPS which used PB for dose calculation. The treatment plans were then re-





Figure 2.11. Dose distributions calculated with PB (g) and MC (h) as well as the corresponding gamma 
distribution (i) for a lung target. Figures j, k and l show line dose and gamma profiles for figures g, h and i 
respectively. Image taken from Yamashita, Akagi (39). 
The work conducted in this study showed that significant differences exist between dose 
distributions calculated with MC and PB especially in the distal fall-off region. This was 
particularly noticed when the proton beam was transported through low density regions as can 
be seen in Figure 2.11 (39).  
In a more recent study, Grassberger et al. studied differences between PB and MC dose 
calculation in a cohort of 19 lung cancer patients treated with proton DS. PB dose calculations 
were carried out using a commercial TPS (XIO) and MC simulations were performed with 





Figure 2.12. Dose distributions calculated with PB (C), MC (D) as well as corresponding DVH (E) and 
difference plot (F) for a lung tumor.  Image taken from Grassberger, Daartz (41). 
Treatment plans were created in XIO using PB for all 54 patients. Re-calculating the treatment 
plans with MC resulted in a mean dose loss of -2.3% to the CTV. Furthermore, this study 
reported that recalculating with MC resulted in a decrease in lung dose for small targets and an 
increase in lung dose for large targets. Finally, MC and PB profiles and depth doses were 
validated against an ionization chamber array measurement in a lung phantom. Analysis 
demonstrated an average difference of 1.6% for MC and 5.6% for PB compared to 
measurement (41).  
In another study, Taylor et al. investigated differences in dose calculation between MC and PB 
using an anthropomorphic lung phantom (49). The lung phantom used in this work was sent to 
five separate proton therapy clinics across the USA. At each clinic a CT scan of the lung 
phantom was acquired and a hidden target volume within the phantom was delineated. CT 
scans were transferred to the TPS of the corresponding clinic and PBS plans were generated to 
irradiate the target volume to a given dose level using PB and MC dose calculation. The lung 
phantom was equipped with several thermoluminescent dosimeters (TLDs) to measure point 
doses as well as gafchromic film to measure profiles. Following PBS beam delivery at each 




where the TLDs and film were analyzed. Figure 2.13 shows dose profiles across the lung 
phantom target as measured with film and calculated with MC and PB.   
 
Figure 2.13. Dose profile across the iGTV of an anthropomorphic lung using film (blue) and calculated with two 
dose calculation algorithms: MC (red) and PB (green) for four proton therapy clinics. Image taken from Taylor, 
Kry (49). 
This study showed that treatment plans calculated with PB over-predicted dose to the target 
volume by an average of 7.2% compared to measurements. In some regions of the target 
volume PB over-predicted dose by up to 46% percent. In contrast, MC-calculated treatment 
plans showed a mean agreement within 4% of measurements and maximum difference of 12% 
(49). 
Finally, Widesott et al. reported on differences between MC and PB dose calculations in a 
variety of treatment sites and delivery conditions using the Raystation TPS. (50). In this work, 
an anthropomorphic head phantom as well as a biological sample were simulated and used to 
create a series of test plans using MC and PB for optimization and dose calculation utilizing 
various combinations of planning parameters including air gap, range shifters and gantry 
angles. For every plan created in this study, beam measurements with an ion chamber array 
were acquired and compared against dose calculations using gamma analysis. Figure 2.14 
shows dose differences and line dose profiles between PB and MC dose calculations in a 





Figure 2.14. Dose distributions of treatment plan generated with PB dose calculation (upper left) and re-
calculated using MC (bottom left) as well as corresponding DVH (upper right), dose difference (bottom right) 
and line dose profiles (bottom middle). Image taken from Widesott, Lorentini (50). 
When compared to the ion chamber measurements, gamma pass rates for MC dose calculation 
were on average approximately 10% higher compared to gamma pass rates for PB dose 
calculation across multiple treatments created using the biological sample as well as an 
anthropomorphic phantom (50). These results agree with other studies mentioned in this 
chapter section that demonstrate the superior dose calculation of MC compared to PB.  
 
2.4 Machine learning applications in proton therapy 
This section will provide a broad overview of ML applications within radiation oncology while 
emphasizing relevant studies dealing with proton therapy and more specifically proton PBS. 




with statistical methods to make predictions or decisions based on collections of data. Figure 
2.15 shows the relationship between the terms artificial intelligence and machine learning.  
 
Figure 2.15. Figure illustrating the relational hierarchy of the following terms: artificial 
intelligence, machine learning and deep learning.  
As shown in Figure 2.15, within the field of ML is a more specific class of predictive models 
that fall under the term of deep learning. Deep learning utilizes specific types of predictive 
models often referred to as artificial neural networks which are inspired by the biological 
networks of an animal brain. ML models can be classified into three broad learning categories: 
(1) supervised learning, (2) unsupervised learning and (3) reinforcement learning as shown in 





Figure 2.16. Illustration of the 3 general types of ML models with corresponding applications types.  
As shown in Figure 2.16, unsupervised and supervised learning models can be further 
categorized into subclassifications: clustering and dimensionality reduction for unsupervised 
leaning algorithms as well as classification and regression for supervised learning models. All 
the studies referenced within this section utilize ML models that can be classified into one of 
three categories shown in Figure 2.16.   
2.4.1 Machine learning for proton MU prediction 
One application of ML to proton therapy that been studied in multiple publications is the 
prediction of MU for passive scattering proton therapy (PSPT) modalities such as uniform 
scanning and double scattering (51) (52). Complexity of various beamline components utilized 
in PSPT as well as variability of these components across different PT systems makes a 
generalized analytical calculation of MU challenging to implement for commercial TPS 
vendors. As most commercial TPSs do not calculate MU values for PSPT, accurate predictions 
of this parameter can streamline QA workflow by avoiding the need to carry out patient-
specific beam measurements although rigorous validation should be carried out before clinical 
use. In one study by Sun et al. a training dataset was compiled that included measured MU, 




ML models for the prediction of MU. Prediction accuracy of these three models (Random 
Forest, XGCBoost and Cubist) were compared against a semi-empirical model described by 
Kooy et al. (53).  
 
Figure 2.17. Histogram plots of the percentage difference (i.e. prediction accuracy) of various ML 
models (a, b, c) in the prediction of PSPT MU compared to a semi-empirical model (d). Image 
from Sun, Lam (51). 
As can be seen in Figure 2.17, all ML models demonstrated superior prediction accuracy 
compared to the semi-empirical model with the Cubist model proving the most accurate results 
(51).  The prediction accuracy presented in Sun et al. is similar in result to the work by Grewal 
et al. (52) in which various neural network (NN) architectures were utilized for MU prediction 





Figure 2.18. Histogram of MU prediction accuracy for 3 different neural network models. 
Image from Grewal, Chacko (52).  
As can be seen in Figure 2.18 the Gaussian process NN model had the best prediction accuracy 
with a mean absolute error (MAE) of 0.61% (52). This gaussian process NN model performed 
very similar to the work by Sun et al. which reported a mean absolute error of 0.62% for Cubist 
model in the prediction of PSPT MU (51). 
2.4.2 Machine learning for CBCT conversion 
Another application of ML to PT is the conversion of cone-beam computed tomography 
(CBCT) images to make them suitable for proton dose calculation. This is an active area of 
research and has been studied extensively (54-59). Due to the Bragg peak, PT dose distributions  
exhibit steep distal dose gradients making accurate beam delivery very sensitive to changes in 
patient anatomy (54, 60). CBCT images can be a useful imaging modality for adaptive 
radiotherapy (ART) within a proton therapy workflow as anatomical change in patient anatomy 
can be accurately evaluated (60). However, due to poor image quality, CBCT images are not 
suitable for PT dose calculation which drives interest in this topic.  
Published work that propose ML solutions in the conversion of CBCT has been summarized 












USED IN STUDY 
 
NN ARCHETECTURE 
Thummerer et al. (54) CBCT to CT Head & Neck U-Net 
Kurz et al. (55) CBCT to CT Prostate GAN 
Hansen et al. (56) CBCT to CT Pelvis U-Net 
Landry et al. (57) CBCT to CT Prostate U-Net 
Harms et al. (59) CBCT to SPR Head & Neck GAN 
 
Table 2.1. Table summarizing selected works which have presented ML-based methods for CBCT conversion. 
Image modified from Wu, Nguyen (61). 
All models presented in Table 2.1 are deep neural network (DNN) architectures of two general 
types: generative adversarial network (GAN) (62) and U-net (63). The methods employed to 
correct CBCTs within these studies fall into two categories: (1) CBCT to CT conversion and 
(2) CBCT to relative stopping power (RSP) conversion. In CBCT to CT conversion, models 
are trained to predict a map of CT-HU values based on CBCT-HU values. The result is the 
generation of a synthetic CT (sCT) which can then be used by a TPS to perform dose 
calculation through conversion of cCT values to RSP values. In the second category, CBCT 
values are converted to RSP values which can be directly used to calculate dose.  
In a study by Thummerer et al. a GAN was trained on 27 H&N patients to predict CT-HU 
values based on CBCT-HU values resulting in a synthetic CT (58). The synthetic CT was then 
used for dose calculation with the Raystation TPS. Multiple model evaluation metrics were 
used including MAE and gamma analysis for assessment of image quality and suitability for 
accurate dose calculation respectively. Figure 2.19 shows a CBCT, synthetic CT and clinical 





Figure 2.19. Images of CBCT (left column), synthetic CT created using a GAN 
model (labeled as cCT CBCT, middle column) and clinical patient CT (labeled 
pCT, right column of a test patient anatomy. Image modified from Thummerer, 
de Jong (58). 
Results of this work show that the GAN model was able to generate synthetic CTs with MAE 
of 40 ± 4 HU compared to clinical CTs. Furthermore, the average gamma pass rate of proton 
dose calculations using synthetic vs. clinical CTs was 96.1% using 2%/2mm pass/fail criteria.  
A similar study was carried out by Guillaume et al. using multiple U-net models to carry out 
corrections of CBCTs for proton and photon dose calculations (57) using clinical data from 
prostate scans. This study was able to achieve MAE values of 48/88/56 HU in the prediction 
CT values based on a test dataset of CBCT images across three different U-net models. In 
Hansen et al. a U-net model was also used for CBCT correction and MAE values of 46 HU 
were reported which is similar to Guillaume et al. and Thummerer et al. (56). Gamma pass 
rates for proton dose calculations on test patients however were much lower and ranged from 
15% to 81% in Hansen et al. (56). Finally Kurtz et al. evaluated the performance of a cycle-
GAN (64) and found the resulting synthetic CT acceptable for VMAT dose calculation but was 




2.4.3 Machine learning for beam delivery error prediction 
Numerous studies have also investigated the use of machine learning applications for 
prediction of MLC delivery error in conventional photon therapy and it is worthwhile to review 
some of these works as well since they relate to the work presented in Chapter 6. In Carlson et 
al. it was demonstrated that ML can accurately predict MLC leaf position errors in VMAT 
treatment deliveries (65). In this study the planned MLC positions from DICOM-RT files were 
compared against delivered positions obtained from LINAC log-file delivery data. Planned and 
delivered MLC positions from a previously treated group of 74 patients receiving VMAT 
constituted the training dataset for ML models. This data was used for training of 3 different 
types of ML models:  (1) linear regression, (2) Random Forest (66) and (3) cubist (67). Models 
were tested on hold-out plans using MAE and root mean square error (RMSE) of MLC position 
prediction as model evaluation metrics. This study concluded that the cubist model 
demonstrated the lowest prediction error and performed best at predicting delivered MLC 
positions. Figure 2.20 shows the cubist model performance along with delivery error of MLC 
positioning for moving MLC leaves and MLC leaves at rest across three different 
clinics/LINACs.  
 
Figure 2.20. Mean absolute error of the prediction of MLC 
positions during VMAT delivery using three different ML models. 
Image taken from Carlson, Park (65).  
Predicted MLC positions were also generated and inserted into DICOM-RT files which were 
subsequently used for dose re-calculation in the TPS for a set of test patients. 2D dose profiles 
were measured with a MapCHECK2 detector array (Sun Nuclear Corporation, Melbourne, FL) 




predicted MLC parameters using gamma analysis. When compared to measurements, predicted 
dose distributions had higher gamma rates than planned parameters using pass/fail criteria of 
3%/3mm, 2%/2mm and 1%/2mm.  
In another study Valdes et al. reported on the use of an analytical model to accurately predict 
gamma pass rates of IMRT deliveries based on multiple plan complexity parameters including 
MU, MLC leaf positions and LINAC type (68). In this work, 498 IMRT treatments were planed 
using the Eclipse treatment planning system (Varian Medical Systems, Palo Alto, California). 
Following planning, feature extraction of plan complexity metrics based on MLC leaf 
parameters and control point MU values was carried out for each plan. Dose profiles at 
standardized depths were measured using a commercial 2D diode array and compared to the 
calculated dose from TPS using a 3%/3mm gamma analysis. A dataset comprising of 
complexity metrics as well as gamma analysis results for each of the 498 IMRT plans was used 
for training of a generalized linear model to predict gamma fail rates using residual error as an 
evaluation metric. Model testing was carried on unseen data and the residual error values (i.e. 
predicted gamma rate – measured gamma rate) of the trained linear model were within +/- 3% 
as shown in Figure 2.21 (68).  
 
Figure 2.21. Histogram plot of the residual error for prediction of gamma fail rate using the generalized 
liner model. Image taken from Valdes, Scheuermann (68).  
To prevent overfitting and to ensure optimal model generalization to unseen data, Lasso 
regularization (69) was employed during model training. The model presented in this study 
served as the basis of a virtual IMRT QA framework which can allow for the early detection 




CHAPTER 3: PENUMBRA REDUCTION FOR 
APERTURE-COLLIMATED PENCIL BEAM 
SCANNING PROTON THERAPY 
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This chapter will present work on improving PBS treatments using aperture collimators.  The 
work presented in this chapter is impactful as it has served as the basis of clinical 
implementation of aperture-collimated PBS treatments at the SCCAPTC and to date numerous 
patients have received treatment using this technique. The motivation for using aperture 
collimators for PBS are enhanced dose sparing of OARs adjacent to the target through 
penumbra sharpening as described in Chapter 2. The research analysis presented in this chapter 
is also novel as it was the first to comprehensively characterize lateral penumbra and validate 
its dose calculation across all relevant treatment planning parameters using a commercial TPS. 
Multiple studies have been carried out on the topic of aperture-collimated PBS as presented in 
Chapter 2.1. Except Baumer et al. (21) these studies did not validate the dose calculation of 
aperture-collimated PBS beams using a clinically commissioned TPS, a process that is required 




Raystation for lateral penumbra calculation of collimated PBS fields for varying energy and 
depths, there was however no mention of the accuracy of penumbra calculation across varying 
airgaps or range shifter thickness both of which are important parameters which can affect PBS 
penumbra. The characterization and validation of the Raystation TPS for collimated PBS fields 
across all relevant planning parameters which can affect lateral penumbra is needed for clinical 
commissioning of aperture-collimated PBS beam delivery.  
There were two primary aims of the work presented in this chapter. The first aim was to validate 
Raystation’s MC dose calculation of lateral penumbra of aperture-collimated PBS beams 
against film for all relevant parameters that affect lateral penumbra including depth, air gap 
and range shifter thickness. In this study lateral penumbra was defined as 80% to 20% distance 
of lateral dose fall-off. The second aim was to comprehensively characterize the reduction in 
lateral penumbra between un-collimated and collimated PBS beam for different values of field 
parameters. These aims were accomplished by validating the TPS-calculated penumbra values 
for various PBS beams against film measurements.  
3.2 Methods and materials 
Measurements for this study were carried out on a fixed PBS beamline. SCCAPTC is equipped 
with a proton delivery system (Proteus PLUS, Ion Beam Applications, Louvain-La-Neuve, 
Belgium) with a cyclotron and energy selection system that generates proton beams ranging in 
energy from 98.5 MeV to 228.5 MeV. Proton beams spots are Gaussian in shape with sigma 
values at isocenter in air ranging approximately from 3.2 mm to 7.3 mm. For PBS treatment 
fields delivered on the fixed beam-line, the PT system is commissioned to deliver a maximum 
field size of 40 cm x 30 cm with a continuous range in water from 7.5 cm to 32.5 cm. For 
shallow targets, at water-equivalent depths of less than 7.5 cm, acrylic range shifters are placed 
at the end of the treatment snout for additional energy modulation. The Raystation TPS at 
SCCAPTC has been commissioned to support a 4.0 cm or 7.5 cm (water equivalent thickness) 
range shifter (13). 
All PBS beams presented in this chapter were planned in Raystation v6.0. which supports two 
dose calculation algorithms: PB dose engine (version 4.1) as well as the MC dose engine 
(version 4.0) (11, 14, 45, 70).  
Each PBS beam in this study was inversely optimized using the following MC dose calculation 
settings:  The dose calculation grid was set to 2 mm and each field was optimized using 10,000 




fractions to the target volume which was the same across all plans and consisted of a rectangular 
cuboid with dimensions of 10 cm x 10 cm at isocenter and varying length along the beam axis. 
A max dose objective of 30.9 Gy (RBE) (i.e. 103% of RX) was placed on the target volume to 
control hotspots and ensure dose uniformity. Each plan consisted of a single beam enface to 
the phantom and was optimized to deliver uniform dose across the target. Other plan setting 
settings used for optimization included an initial spot placement target margin of 0.6 cm with 
energy and inter-spot spacing of 1 cm and 0.5 cm respectively.  Following the completion of 
200 iterations a final dose calculation was carried out using MC with a statistical uncertainty 
of 0.5%.  
 
Figure 3.1. (A) Lateral dose distribution of a single proton beam optimized to deliver uniform dose the target 
(white contour) in a water phantom (blue volume) using a collimated PBS beam and 4.0 cm range shifter. (B) 
Beams eye view illustrating the isocenter (orange crosshair), the PBS beam spot pattern (orange dots) shooting 
through the aperture opening.  
Each beam was copied, and brass apertures of 6.5 cm thickness were added within the TPS.  




calculation as the un-collimated beams. An illustration of one of the optimized PBS beams with 
aperture is shown in Figure 3.1. 
First, the characterization of PBS penumbra with depth was analyzed in the following manner: 
Three separate treatment fields were optimized independently such that 95% of the target 
volume was covered by 95% of the prescription dose (i.e. D95%=30 Gy (RBE)). These three 
fields corresponded to three different range shifters: 0 cm (RS0), 4.0cm (RS40), and 7.5cm 
(RS75). The physical thicknesses of the acrylic range shifters used at SCCAPTC are 3.5 cm 
for RS40 and 6.5 cm for RS75.  
Beam specific target volumes of field size 10x10 cm were created such that beams would have 
the max residual range and SOBP width for each range shifter. This max residual range 
corresponded to a proton beam energy of 221.9 MeV at nozzle entrance. This resulted in three 
PBS plans with range and SOBP width as follows: (i) residual range 31 cm, SOBP width 23 
cm for RS0, (ii) residual range 27 cm, SOBP width 23 cm for RS40, and (iii) residual range 
23.5 cm, SOBP width 23 cm for RS75. Following optimization, dose files were exported and 
analyzed in DoseLab (version 6.60, Mobius Medical Systems LP, Bellaire, TX, USA). Lateral 
penumbra (80%-20% distance) was recorded at 2 cm intervals in depth along each target 
volume for the un-collimated PBS beams.  
Next, brass aperture collimators were applied in the TPS and each field was re-optimized using 
MC dose calculation. Lateral penumbra of the collimated fields was then re-analyzed at 2 cm 
intervals along each target volume. For fields using a range shifter, the central airgap between 
phantom and rang shifter was set to 5 cm. Within the TPS air gap is defined as the distance 
between the downstream range shifter surface and upstream phantom surface. In this 
configuration, the distance from isocenter to the downstream surface of RS40 and RS75 was 
20 cm. In the TPS, apertures are placed directly upstream from the range shifter. The 
corresponding distance from isocenter to the downstream surface of the brass apertures was 
20cm, 23.5cm and 26.5cm when using RS0, RS40 and RS75 respectively.  
Next, TPS dose profiles were compared against film to validate the MC penumbra calculation 
of aperture-collimated PBS beams. For this, all aperture-collimated PBS fields were transferred 
to the MosaiqTM (Elekta, Sweden) radiation oncology information system. Non-divergent brass 
aperture collimators were then milled in-house to mimic the aperture shape as planned in the 
TPS. TPS measurement conditions were mimicked by placing Gafchromic EBT3 (Ashland, 




couch and each film was placed at specified depths. The treatment couch was then positioned 
to align the solid water to treatment isocenter prior to beam delivery. Irradiated films were 
scanned 24 hours after exposure using a flatbed scanner (Epson Expression 11000XL, Epson 
America Inc., CA) and each pixel value was converted to optical density (OD). A non-
irradiated film was also scanned in the same setup and subtracted from the irradiated films to 
account for background. Finally, the OD files were converted to absolute dose value through a 
calibration curve. Scanner resolution was set at 72 pixels per inch in the landscape orientation. 
Digitized films were exported to DoseLab software where lateral penumbra values measured 
with film were calculated and recorded. 
Next, characterization of PBS penumbra and air gap between the range shifter and patient 
surface was studied. For this, six beams of varying air gaps ranging from 5 - 30 cm in 5 cm 
increments were generated using the RS40 and RS75 range shifters. Note that use of RS0 was 
excluded because the air gap is undefined in this case. For each beam, the target volume 
consisted of a 10x10x10 cm3 cube centered at depth of 15 cm inside a homogenous water 
volume resulting in a beam of range 20 cm with SOBP width of 10 cm. Following optimization, 
dose files were exported, and lateral penumbra was evaluated at depths of 7, 11, 15 and 19 cm 
using DoseLab. Next, collimators were applied in the TPS and each field was recalculated 
using the same dose and optimization as mentioned previously. The resulting lateral penumbra 
values were analyzed at the same intervals as the uncollimated fields. 
3.3 Results 
Application of an aperture collimators to PBS beams resulted in a reduction in lateral penumbra 





Figure 3.2. (A): TPS-calculated 2D dose distributions for a PBS beam with and without collimation in a water 
phantom at 9 cm depth without range shifter and (B) 1D TPS-calculated dose profiles showing lateral penumbra 
for a collimated (blue line) and un-collimated (red line) PBS beam. The white line in (A) indicates the location 
of the profiles shown in (B). 
Reduction in PBS lateral penumbra due to collimation decreased with increasing depth in water 
and was most pronounced for shallow targets. Figure 3.2 shows the lateral penumbra for a PBS 
beam in homogenous geometry with and without collimation as calculated by the TPS. The 
reduction in penumbra with collimation versus without collimation is clearly observed. The 
plots in Figure 3.3 show lateral penumbra as calculated by RS-MC and measured with film for 
the collimated and un-collimated fields for varying depths and range shifter thicknesses. All 
film-measured values of lateral penumbra matched RS-MC within +/- 1 mm (maximum 






Figure 3.3. Calculated and measured lateral penumbra illustrating the comparison of penumbra with and without 
collimation for three different beams with varying range shifter thicknesses, range, and SOBP width. (A): range 
31 cm, SOBP width 23 cm, RS0. (B): range 27 cm, SOBP width 23 cm, RS40. (C): range 23.5 cm, SOBP width 




As can be seen in Figure 3.3, the magnitude of lateral penumbra increased approximately 
linearly with depth for all three range shifters with and without aperture collimation. With 
varying range shifter thickness and same SOBP width, excellent agreement was observed 
between the penumbra values calculated with RS-MC and those measured with film. 
A scatter plot of lateral penumbra reduction (i.e. un-collimated minus collimated penumbra) 
vs. depth is presented in Figure 3.4. Linear regression curves are overlaid onto the scatter plots 







Figure 3.4. Comparison of TPS-calculated lateral penumbra reduction with and without aperture collimation for 
the three different range shifter thicknesses. 
As shown in Figure 3.4, the linear slope of penumbra reduction is -0.10 mm/cm for RS0 and -
0.16 mm/cm for RS40 and RS75. At 2 cm (i.e. the shallowest depth), penumbra reduction was 
2.7 mm, 3.7 mm and 4.2 mm for RS0, RS45 and RS75 respectively. Penumbra reduction was 
reduced to 1 mm at a depth of approximately 23 cm for RS0 and 20 cm for RS40 and RS75.  
Figure 3.5 shows the lateral penumbra values for air gaps ranging in value from 5 cm to 30 cm 







As shown in Figure 3.5 lateral penumbra increases approximately linearly with both depth and 
air gap for both RS40 and RS75. For RS40 without collimation, the lateral penumbra increased 
from 7 mm (depth 7 cm, air gap 5 cm) to 13 mm (depth 19 cm, air gap 30 cm). With collimation, 
the penumbra increased from 5.1 mm (depth 7 cm, air gap 5 cm) to 12.6 mm (depth 19 cm, air 
gap 30 cm). For RS75 without collimation, the lateral penumbra increased from 7.5 mm (depth 
7 cm, air gap 5 cm) to 14.9 mm (depth 19 cm, air gap 30 cm). With collimation, the lateral 
penumbra increased from 5.7 mm (depth 7 cm, air gap 5 cm) to 14.8 mm (depth 19 cm, air gap 
30 cm). All TPS-calculated lateral penumbra values of PBS-collimated fields matches film 
measurements within +/- 1 mm (max variation = 0.9 mm, mean variation = 0.3 mm, standard 
deviation = 0.2) across all combinations of air gap and depth.  
Applying a 2nd order polynomial surface fit to the penumbra reduction (PR) as a function of 
depth and airgap results in the following relationship:  
                                 𝑃𝑅 𝐶 𝐶 𝐴𝐺 𝐶 𝑑 𝐶 𝐴𝐺 𝑑 𝐶 𝐴𝐺 𝐶 𝑑  (Equation 1) 
Figure 3.5. Variation of TPS-calculated lateral penumbra (y-axis) vs. air gap (x-axis) at various depths for 




where d is the depth in water and AG is the airgap between the phantom surface and range 
shifter.  The fitting parameters, 𝐶  𝐶 , for Equation 1 are shown in Table 3.1 for RS40 and 
RS75.  
  𝑅𝑆40 𝑅𝑆75 
𝐶  2.39 2.07 
𝐶  5.53 𝑥 10  6.95 𝑥 10  
𝐶  4.49 𝑥 10  2.73 𝑥 10  
𝐶  2.16 𝑥 10  2.17 𝑥 10  
𝐶  1.07 𝑥 10  9.29 𝑥 10  
𝐶  4.30 𝑥 10  4.66 𝑥 10  
 
Table 3.1. Fitting parameters for a 2nd order polynomial surface fit of penumbra reduction as a function of depth 
and airgap.  
Figure 3.6 shows 2D contour plots Equation 1 for the RS40 and RS75 range shifter penumbra 






Figure 3.6. 2-D contour plot illustrating TPS-calculated lateral penumbra reduction as function of airgap and 
depth for RS40 (A) and RS75 (B).  
Figure 3.6 shows that penumbra reduction is largest at shallow depths and small air gaps when 
using both RS40 and RS75. Penumbra reduction decreased as both the depth and air gap are 
increased.  
Next, a clinical example patient is presented here to compare penumbra reduction between 
collimated and un-collimated PBS treatment fields. The field arrangement for this treatment 





Figure 3.7. 3D view of the beam arrangement used in the clinical example 
on a test patient.                         
Figure 3.8 shows axial dose distributions of the un-collimated PBS plan (A), collimated PBS 





Figure 3.8. Axial dose distributions for the un-collimated PBS plan (A), collimated PBS plan (B) dose 
difference (C) and line dose profile across the two treatment plans (D).  
The line dose profiles in Figure 3.8 were analyzed in DoseLab and had an average (right-left) 
lateral penumbra of 1.25 cm for the un-collimated PBS plan and 1.02 cm for the aperture-
collimated plan. The resulting average reduction in penumbra along the right and left side of 
the patient target in the axial view as shown in Figure 3.8 is therefore 2.3 mm. This value agrees 
well with Equation 1 which yields a lateral penumbra reduction calculation of 1.9 mm when 
using the fitting parameters shown in Table 3.1, an airgap of 5 cm and depth of 6 cm which is 
the approximate depth the target (red contour) shown in Figure 3.8. 
Figure 3.9 shows the corresponding DVH for the collimated and un-collimated PBS plans 





Figure 3.9. Dose volume histogram for the PTV, optic nerve, chiasm, pituitary and hippocampus for PBS plans 
optimized with and without aperture collimation.  
As can be seen in Figure 3.9, target dose is maintained while dose to several nearby OARs is 













ROI vol. [cm3] 
 
Dose [cGy] 
D99 Average D1 
PBS - Collimated Chiasm 0.29 629 3063 5050 
PBS - Un-collimated Chiasm 0.29 2124 3922 5049 
PBS - Collimated Hippocampus R 1.27 85 1440 4908 
PBS - Un-collimated Hippocampus R 1.27 608 2261 4924 
PBS - Collimated Optic Nerve L 0.51 4 47 945 
PBS - Un-collimated Optic Nerve L 0.51 5 209 2647 
PBS - Collimated Optic Nerve R 0.51 2 54 947 
PBS - Un-collimated Optic Nerve R 0.51 4 239 2675 
PBS - Collimated Pituitary 0.49 265 1047 2926 
PBS - Un-collimated Pituitary 0.49 1362 2423 3764 
PBS - Collimated PTV 59.21 4948 5141 5249 
PBS - Un-collimated PTV 59.21 4967 5138 5252 
 
Table 3.2. Dose statistics for the PTV and multiple OARs showing various dose statistics for collimated and un-
collimated PBS plans.  
3.4 Discussion 
In this study, the variation in lateral penumbra as a function of depth, air gap, and range shifter 
thickness for collimated PBS beams using the Raystation TPS was quantified. The results of 
this study showed that air gap, depth, and range shifter thickness affect the reduction in the 
lateral penumbra that can be achieved through aperture collimation.  
Lateral penumbra reduction through aperture collimation diminished with depth. This was 
primarily due to increased proton scatter as beam spots traversed the medium. At increased 
depths, penumbra broadening of collimated beams along field edges due to scattering within 
the patient approached the lateral penumbra of un-collimated PBS beams. Therefore, use of 
collimation for PBS fields may not be beneficial for deep-seated tumors such as prostate or 
other abdominal treatment sites. The lateral penumbra reduction with collimation was 
negligible (at less than 1 mm) at large depths greater than approximately 20 cm. It is also 
important to note that penumbra reduction through aperture collimation is dependent on PBS 
spot size. This means that PBS systems that have larger spot sizes may benefit from aperture 




In this work it was found that for varying depth, airgap and range shifter thickness, the RS-MC 
dose algorithm calculated the lateral penumbra accurately. For the collimated fields across 
multiple depths and range shifter thicknesses, MC calculation matched film measurements of 
lateral penumbra within +/- 1 mm. Other studies have also demonstrated good agreement 
between RS-MC and measurements of un-collimated fields (11, 71). Saini et al. validated the 
Raystation MC dose calculation against film measurements in a heterogeneous environment 
using an Alderson–Rando phantom and found that 6 out of 7 lateral dose profile planes had 
gamma pass rates greater than 90% using a dose difference of 3%(global) and a distance to 
agreement (DTA) of 3mm  and low-dose threshold of 10% (11). In a similar study, Sorriaux et 
al. found a 95.9% (2%(local)/2mm gamma index criteria) agreement between Raystation MC 
and measurements made with an ion chamber array in an anthropomorphic phantom (71).  
This chapter has also presented a treatment plan generated in Raystation using a patient CT in 
which un-collimated and collimated PBS beams were optimized and the penumbra across the 
target volume was compared. Baumer et al. has carried out a similar study using Raystation in 
which a collimated PBS treatment plan was compared against a US plan for the irradiation of 
an ocular orbit (21). Comparisons of the order of range shifter and aperture and the impact on 
lateral penumbra were also studied by Baumer et al. The work presented in this chapter differs 
with Baumer et al. in that the difference in penumbra with and without aperture collimation 
across multiple planning parameters was investigated. Furthermore, this work has derived an 
analytical formula to predict the lateral penumbra based on depth of target and air gap. This 
analytical formula can be used by clinicians during planning to decide whether aperture 
collimation would have dosimetric benefit for patients who are to receive PBS treatments.  
The analytical formula had the following limitations. First, it was derived in homogeneous 
media and may not account for scatter caused by heterogeneities found within patient anatomy. 
This limitation could cause discrepancies based on differing scatter properties between 
homogeneous and heterogeneous media. Second, the formula was derived for properties of 
single beams impinging on a rectangular target. Although this approximation is common in 
routine radiotherapy quality assurance, patients often receive multiple beams impinging on 
rounded surfaces. As a test of the robustness of the model against these specific limitations, a 
clinical patient example in which three fields targeted a tumor volume located in the brain of a 
heterogeneous patient CT was selected. Even with these potential limitations, the penumbra 
values predicted by Equation 1 agreed well with the TPS-calculated penumbra of the clinical 




derived using spot sigma values ranging from 3.2 mm to 7.3 mm. Therefore, Equation 1 along 
with the fitting parameters in Table 3.1 may not be valid for proton therapy systems with spot 
sizes drastically different than that used in this work. Future studies may investigate the effects 
of adding additional terms to the analytical penumbra model that consider heterogeneities 
within the patient as well as varying PBS spot sizes. 
Although use of apertures for PBS fields allows for some dosimetric advantages for certain 
patients/disease sites via sharper penumbras, there are various limitations to consider for 
clinical implementation. Firstly, the added duration to the treatment planning timeline needed 
for utilizing apertures for PBS fields should be considered. Milling of field apertures must take 
place prior to QA/treatment, takes time and can add to the cost of treatment. Additional patient 
QA tests should also be performed prior to treatment to ensure that the milled aperture shapes 
match the TPS within an appropriate tolerance. Use of apertures can also add to the treatment 
time as they must be switched out in between beam deliveries. Finally, various studies have 
investigated increased out-of-field dose due to neutron contamination as well as increased dose 
averaged LET within the field when using apertures with PBS fields (72-74). It is therefore 
important for clinicians to assess these timeline and radiation protection considerations prior 
to clinical implementation of PBS apertures.   
3.5 Conclusion 
In conclusion, the findings presented in this chapter show that apertures can measurably 
sharpen the lateral penumbra of PBS fields. The lateral penumbra of collimated PBS beams 
varied as a function of depth, airgap and range shifter thickness. The results demonstrated that 
the use of apertures for PBS treatments is most beneficial for shallow targets while maintaining 
small air gaps. At approximately 20 cm depth, the benefit of using an aperture diminished with 
penumbra reduction reducing to less than 1 mm. Furthermore, it was found that the Raystation 
MC dose engine calculated lateral penumbra with sufficient accuracy for clinical use. PBS 
penumbra reduction through collimation was also demonstrated on a clinical CT scan for a 
brain case and the corresponding DVH and dose statistics for the target and affected OARs 
were presented. Finally, an analytic equation which can predict lateral penumbra reduction 
between collimated and un-collimated PBS treatments as a function of target depth and airgap 
was introduced. This analytic equation was able to predict the penumbra reduction to within 
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4.1 Introduction 
Recently the Raystation TPS (version 9B) has added new 6D couch features that allow for 
radiotherapy treatments in the seated position. In this chapter, the aim will be to validate and 
provide readers with a guideline for the practical implementation of these new features for 
chair-based treatments. Chair-based treatments have been shown to be a cost-effective solution 
for particle therapy centers that have partial or fixed PBS beamlines (34, 75-78). Over the past 
5 years, more than 300 ocular patients have been treated in the seated position using a treatment 
chair at SCCAPTC. These patients were treated using uniform scanning with treatment 
planning carried out using the XiO TPS (Elekta Instrument AB, Stockholm, Sweden). Although 
SCCAPTC has adopted Raystation as its primary TPS due to its modern design, functionality, 
and ease of use, treatments in the seated position had to be planned in XiO due to a lack of a 
chair feature in previous versions of Raystation. This resulted in SCCAPTC spending extra 
resources in supporting an additional TPS for the sole purpose of chair-based treatments. The 




similar to SCCAPTC by providing an avenue to move to a single TPS for all proton treatments. 
Additionally, centers with fixed beamlines have the potential to expand their treatment delivery 
capabilities by implementing chair-based treatments.  
Most current commercial TPSs offer only a flat couch top as a patient support device for 
planning and treatment positions are limited to prone or supine patient orientations. Clinicians 
can modify beam direction through a combination of gantry angle and/or couch rotation. In the 
Raystation TPS, existing planning features are supplemented with several 6D couch features: 
(i) an option to have patient support to be either a flat treatment couch or a chair, (ii) an 
additional patient treatment orientation of ‘sitting’, and (iii) allowing patient support devices 
to have additional degrees of freedom in the form of pitch and roll. In the sitting orientation, 
the Raystation TPS rotates the image volume such that a head-first-supine (HFS) or feet-first-
supine (FFS) scan can be planned with the superior-inferior axis parallel to the IEC treatment 
room z-axis. These additional features can be configured to have a streamlined workflow for 
chair-based proton therapy delivery. Along with other advanced capabilities offered in the 
Raystation TPS, particle therapy centers can modernize their chair-based treatments.  
The overall aims of this chapter are to validate the Raystation TPS implementation of the 6D 
couch features and provide an implementation strategy for chair-based treatments in the 
following 2 steps: 
1) The implementation of extra degrees of freedom for couch motion (pitch and roll) were 
verified. 
2) Practical implementation of the 6D couch features for treatment in the seated position 
in a chair is described. An end-to-end test using an anthropomorphic phantom was 
carried out to fully validate the workflow of treatment. 
4.2 Materials and methods 
4.2.1 Relevant equipment and software 
SCCAPTC is a four-room proton therapy facility with capabilities to treat patients using PBS 
and US. Patients are simulated with a GE Optima 580W CT scanner (GE Healthcare, 
Waukesha, WI). MOSAIQ (version 2.64) (Elekta Medical System, Sweden) oncology 
information system is used to monitor and schedule patient treatments. For the work presented 
in this chapter, treatment planning was performed with Raystation (version 9B) TPS. Couch 




Imaging, Middleton, WI). Orthogonal x-ray images were acquired and analyzed through the 
Medcom Verisuite Imaging System (Ion Beam Applications, Louvain-Neuve, Belgium). 
Patient-specific 2D dosimetric measurements were acquired through Gafchromic EBT3 film 
(Ashland Advanced Materials, Wayne, NJ) and MatriXX PT ionization chamber array (IBA 
Dosimetry, Schwarzenbruck, Germany). 2D dosimetric analysis of the film and ion chamber 
array measurements were performed in the OmniPro I’mRT (Ion Beam Applications, Louvain-
Neuve, Belgium) software. 
4.2.2 Validation of 6D couch features 
All treatment couches at SCCAPTC adhere to translation and rotation conventions outlined in 
the IEC standard 61217, which specifies the direction as well as the order of radiotherapy 
treatment couch rotations. To verify that simulated rotations (pitch, roll, and yaw) in RS were 
consistent with IEC61712 several treatment plans with varied couch orientations were 
generated and translated through Mosaiq to the IBA couch positioning system. These couch 
rotations were applied and then measured with a digital level to ensure they were correct. For 
a subset of treatment beams, the rotations were also verified by comparing TPS-generated 
digitally reconstructed radiographs (DRRs) of a previously-scanned MIMI phantom (Figure 
4.1) to orthogonal planar x-rays images. For the acquisition of x-ray images, the MIMI phantom 
was aligned to isocenter and the associated couch rotations for each beam was applied. The 
DRRs and x-ray images were overlaid and compared against each other in the Verisuite 
imaging software. 
Additional dosimetric tests were performed to ensure that RS correctly orients treatment beams 
onto the patient image for various patient position settings and couch rotations. For these tests 
a head phantom was scanned with two different orientations (HFS and FFS). Twelve test beams 
with different couch rotations were created for the two scanning orientations (Table 4.1). A 
TPS screenshot of beams with several pitch angles is shown in Figure 4.2. Treatment beams 
consisted of a single layer PBS beam with an asymmetric field shape to enable easy verification 
of orientation. Figure 4.2 (b) shows the BEV of three fields with various pitch/roll 
combinations. All 12 beams were mapped onto a phantom geometry designed to model the 
MatriXX PT ion chamber array using the QA plan generation tools in Raystation. Because the 
intent is to test the correct orientation of the beam when couch rotations are applied, couch 
rotations and gantry angles were all retained in the QA geometry within the TPS. Beams were 




was placed on a 360-degree rotational mounting device affixed to the treatment couch as shown 
in Figure 4.3. Use of this mounting device allowed for the application of rotations to the 
MatriXX PT in the treatment room that mimicked 6D couch rotations simulated in the TPS.  
Measured planes were first visually compared to the TPS BEV dose to ensure correctness of 
beam orientations and shapes. Measured planes were also compared to TPS-generated planes 
for gamma index analysis using a DTA of 3 mm and dose difference of 3%. 
 
 
Figure 4.1. Picture of the MIMI phantom used for verification of couch rotations (A) 
and screen shots from the TPS of the phantom CT in the axial (B), sagittal (C) and 





Table 4.1. Table showing the test beams used with various combinations of scanning orientation, treatment 
orientation and 6D couch rotations.  
 
 
Figure 4.2. (a) 3D representation of the patient along with beams of different pitch angles with the patient in the 
seated position. (b) BEV corresponding to three beams with pitch and roll rotations for a phantom to be treated 






Figure 4.3. Screen shot from the TPS showing phantom rotations in a QA plan (left) and corresponding 
measurement with an ion chamber with applied rotation to simulate chair or tabletop rotation (right).   
4.2.3 Treatment chair implementation 
At SCCAPTC, seated treatments are performed utilizing a commercial treatment chair (RT-
4534, Qfix, Avondale, Pennsylvania).  The patient’s head rests against a curved neck support 
frame and is secured by a thermoplastic mask. The back insert is battery-powered and can be 
adjusted to account for a patient’s height. The chair is compatible with standard BoS masks 
that can be used to immobilize the patient’s head. There are adjustable arm and foot supports 
that can be set to a patient’s comfort. The chair mounts on a fixed robotic base that allows for 
pitch, roll, and yaw corrections, which can be applied during image guided radiation therapy 
(IGRT) alignment. The robotic base allows for the chair to be swapped with a traditional couch 
top for treatments in supine or prone positions.  
Patient support type in the TPS beam model was changed to “Chair” to accurately simulate the 
patient in the sitting position. The TPS beam model also has options to define relevant pitch 
and roll limits which can be set accordingly. If using the same beamline for both chair and a 
traditional flat top couch, two beam models for the same beam could be commissioned in 
Raystation: one with Chair as a patient support type and the other with Table as a support 
device. Finally, the chair has a fixed recline of 20 degrees with a back support insert. This 
treatment chair recline is implemented in Raystation through a +20-degree table-top pitch with 
the patient position set to sitting for a HFS scan. It is important to note however that the pitch 
angle must be set to zero in the MOSAIQ software when translating plans since the 20-degree 




In addition to the aforementioned TPS settings, chair settings also need to be defined in the 
oncology information system so that DICOM plans with chair tags can be imported. In 
MOSAIQ version 2.64, chair parameters can be included in the Machine Characterization 
Editor. With this version of Mosaiq the two required tags are Chair Pitch Angle and Chair Roll 
Angle. The addition of these two tags enables the chair pitch and roll parameters to appear in 
the treatment setup and field definitions within MOSAIQ. 
4.2.4 End-to-end testing 
End-to-end testing was carried out using an anthropomorphic head phantom. The process of 
phantom CT simulation and treatment delivery was designed to follow the actual clinical 
protocol at SCCAPTC. The head phantom was simulated HFS using the ocular CT protocol. 
Phantom immobilization was conducted using a thermoplastic mask and mold care which were 
affixed to the neck support frame as shown in Figure 4.4. Radiopaque BBs were placed on the 
mask for localization purposes and the phantom CT was imported into the TPS. A pseudo target 
in the ocular region was created and treatment planning was performed using US proton beam 
delivery with two beams: AP and RLAT. For the uniform scanning beamline at SCCAPTC, 
the proton beam is shaped distally by a wax compensator and laterally by a brass aperture. 
Additional details of a uniform scanning beamline are described in Nichiporov et al (79). For 
treatment planning, beam-specific apertures and compensators were conformed to the target 
volume to ensure optimal dose conformity. The dose to the target volume was 50 Gy in 5 
fractions. Phantom dose distributions in three orthogonal planes and associated beam 
arrangements are shown in Figure 4.5. The treatment plan, CT images, and structure set were 
then transferred to MOSAIQ for beam delivery. As previously mentioned, the couch pitch 
value transfers as 20 degrees from the TPS to MOSAIQ and was manually changed to zero to 
account for the chair’s physical recline. For this work, relative dosimetry of the designed plan 





Figure 4.4. Pictures of the anthropomorphic head phantom setup on the CT table with neck support and 
thermoplastic mask (right and middle) and in-room setup using the treatment chair (right).   
4.2.5 Phantom patient-specific quality assurance 
Prior to end-to-end testing, the phantom plan was mapped to a solid water phantom used for 
patient-specific QA. Dose profile measurements were then obtained using Gafchromic film 
sandwiched between proton-compatible solid water slabs. Film-measured and TPS-calculated 
dose profiles were compared with gamma index analysis using 3% /3 mm pass/fail criteria. 
4.2.6 Phantom treatment simulation 
The CT images along with associated structure set and treatment plan was then transferred to 
Verisuite for IGRT. The phantom and associated immobilization accessories were immobilized 
in the treatment chair and set up to the isocenter using the BBs which were placed during 
simulation. Orthogonal x-ray images were acquired at each chair location and compared to the 
DRRs for treatment setup localization. Appropriate shifts were applied until the phantom was 
aligned within 1 mm in A-P, S-I, and R-L directions. Once aligned, BEV x-ray images were 
obtained with beam-specific apertures in place. These BEV images were compared to the 
corresponding DRRs obtained from the TPS to ensure a visual match between the simulated 





Figure 4.5. Screenshot from the TPS showing the treatment plan generated from on the anthropomorphic head 
phantom as the part of end-to-end testing of the Raystation 6D couch features.  
4.3 Results 
4.3.1 Validation of 6D couch features 
Pitch, roll, and yaw rotations in Raystation were consistent with IEC standards which are 
illustrated in Figure 4.6. The direction of rotation and magnitude in the TPS was consistent 
with the physical couch in the treatment room. Figure 4.7 shows the orthogonal DRRs and x-
ray images of the MIMI phantom for select treatment fields. The DRRs were found to have an 
acceptable agreement with planar x-rays based on visual inspection. The 3%/3 mm gamma 
index analysis between measured and calculated dose profiles for a subset of beams is shown 
in Figure 4.8. The maximum, minimum, and average pass rates for all fields were 99.6%, 




beams agreed between measured and delivered dose profiles. The workflow within the 
Raystation TPS was successful in reproducing correct field shape and orientation as requested 
by the planner.  
 
 
Figure 4.6. Pitch and roll axis of rotation and direction were compared between Raystation and the actual 
treatment couch across multiple couch rotations. The Raystation implementation is consistent with IEC 61217 
standard. A1 and A2 illustrate pitch and roll definitions for couch rotations at either 0 and 180 degrees. B1 and 






Figure 4.7. Comparison of TPS DRRs against planar X-ray images for various combinations of, couch rotations 





Figure 4.8. 2-D Gamma (3%/3mm criteria) index analysis for a subset of beams given in Table 4.1. 
4.3.2 Phantom patient-specific quality assurance 
Aperture overlays were obtained by printing TPS-generated aperture profiles to actual physical 
scale. Brass apertures were milled in-house and then positioned on top of the aperture overlay 
printout to ensure correctness of the field opening within ± 1mm.  
The treatment beams were also delivered to a solid water phantom to be measured individually 
by Gafchromic film sandwiched between slices. For this irradiation, the field parameters 
(couch and gantry angles) were positioned to have en-face orientation for irradiation. 
Measurement conditions such as isocenter location and film depth corresponded to mapped 
phantom conditions in the TPS. Each measured beam was compared to the corresponding TPS-
generated 2D dose profile. The resulting gamma index analysis for these fields had pass rates 





4.3.3 Phantom treatment simulation 
The phantom treatment was performed in the same fashion as actual treatments for chair-based 
patients SCCAPTC to ensure consistency with current clinical practice. A radiation therapist 
assisted in the alignment of the phantom to its treatment position using IGRT. The phantom 
was successfully imaged and subsequently aligned at both chair positions with a residual error 
less than 1 mm. The phantom anatomy as viewed on BEV IGRT images in Verisuite matched 
visually with a TPS-generated BEV DRR. Both the beams were successfully delivered to the 
phantom.   
4.4 Discussion 
Today there are numerous particle therapy centers treating with chair-based radiotherapy in the 
seated position. Chair-based treatments may also be needed for some patients who cannot 
tolerate lying flat either due to cancer or other underlying condition (23, 32, 80). This work has 
verified that Raystation’s implementation of the pitch, roll, and yaw is consistent with IEC 
standard 61217 and matches the physical couch positioning system as measured in the 
treatment room. Furthermore, it was verified that the TPS-generated DRRs matched the planar 
x-ray images that were acquired with a phantom positioned on the treatment table. All the 
treatment couch pitch, roll and yaw rotations were applied automatically through a robotic 
positioning system. Additional dosimetric validation was performed using 12 fields with varied 
scanning and couch rotation settings. The gamma index passing rate for all beams was greater 
than 95% using 3%/3mm pass/fail criteria. This verified that the newly added 6D couch 
features can be successfully integrated into a clinical workflow for support of treatments in a 
seated position. In the end-to-end test, the viability of chair-based treatments was demonstrated 
through an ocular case example in relative dosimetry mode. It is important to note however 
that additional considerations for absolute dosimetry of small fields (~2 cm) that are 
encountered in ocular-based treatments were not considered in this work and users should 
validate their small field dosimetry if this workflow is to be used for treating small targets.  
The work presented in this chapter has the potential to help particle therapy centers with fixed 
beamlines. The methods described in this work can serve as a template for other centers 
attempting to implement chair-based workflows using the 6D couch features with Raystation 
or other treatment planning systems. Raystation’s 6D couch features also provide additional 
flexibility by allowing users to change chair-back angles during the planning process allowing 







The newly added 6D couch features in Raystation were found to have implementation that is 
consistent with IEC 61712 standards. The functionality of these features can be easily 
combined to enable a seamless workflow for treatments in the seated position. Validation of 
this treatment chair in the Raystation TPS will allow for treatment of additional disease sites 
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5.1 Introduction  
PBS proton therapy has been used to effectively treat a multitude of oncologic disease sites 
(12). Lung cancer, particularly in the setting of locally advanced disease, is commonly treated 
with PBS. For treatment planning of this disease site, many technical challenges must be 
considered including respiratory motion-induced interplay effects (81, 82) as well as tissue 
density heterogeneities and overrides within and proximal to the target volume (83). 
Traditionally, the standard dose calculation technique for this type of anatomical site has relied 
on analytical PB dose calculation algorithms (84) as this has historically been the only available 
solution across commercial proton treatment planning platforms. Many of these analytical dose 
algorithms are based on the works of Hong et al. (45) and Schaffner et al. (46). Analytical 
algorithms such as PB algorithms allow for fast and efficient computation but are less accurate 




commonly found within patient anatomy. Furthermore, variations in dosimetry from differing 
proton therapy dose calculation algorithms can have future effects on tumor control probability 
and normal tissue complication rates (85). 
Recently, Raysearch Laboratories has incorporated a commercial MC dose calculation 
algorithm which was first introduced in the Raystation version 6.0 TPS (13). The inclusion of 
MC within a TPS moves beyond in-house solutions (36) and facilitates clinical implementation 
of increased accuracy in dose calculation for complex disease sites such as lung lesions. Fast 
MC dose calculation within Raystation is facilitated through the use of multiple variance 
reduction techniques including use of a continuous slowing down approximation for energy 
loss of heavy secondary particles as well as the exclusion of secondary delta electron transport 
(70).  
Many previous studies on MC dose calculation for small proton fields (40), as well as 
comparisons of PB vs MC, have been limited to phantoms studies (11, 38, 49, 86). While these 
investigators have characterized a range of dose calculation errors under different conditions 
they did not explicitly evaluate dosimetric effects on clinical patient data. Increased 
understanding of MC dose calculation and the impact of optimization on clinical treatment 
planning of lung lesions relative to PB dose calculation and optimization could reveal important 
tradeoffs in plan quality and establish realistic goals for proton therapy dosimetry. 
In this chapter, lung cancer treatment planning between PB and MC dose engines in clinical 
PBS plans was investigated through a retrospective analysis of a select patient cohort treated 
at SCCAPTC. This retrospective analysis of 10 lung cancer addresses the following 3 topics: 
(1) differences in dose to targets and OARs when PB-optimized treatment plans are re-
calculated with MC, (2) difference in target coverage/uniformity and dose to OARs between 
PB-optimized and MC-optimized plans and (3) difference in robustness to setup and range 
uncertainties between perturbed doses of PB-optimized and MC-optimized treatment plans. 
 
5.2 Methods  
5.2.1 Patient cohort  
With Institutional Review Board approval, planning data from 10 previously-treated lung 
cancer patients receiving PBS to the thorax were reviewed and analyzed. Five patients 




combinations of treatment modalities including adjuvant radiation and concurrent 
chemoradiation. The remaining five patients were enrolled onto a clinical trial (NCT02773238) 
that employed a functional lung avoidance optimization technique (87) with the strict eligibility 
criteria. Patients on this trial were treated to at least 60 Gy (RBE) in 30 fractions. Across all 10 
patients, tumor volumes ranged from 81 cc to 637 cc with a median of 261 cc. All tumor 
volumes contained areas of heterogeneity characterized by lung-tissue interface. 
 
5.2.2 Simulation technique  
Patient CT simulation was performed utilizing a free-breathing acquisition of 4D computed 
tomographic (4DCT) imaging using a GE Optima CT580 scanner. Patient CT settings included 
a tube potential setting of 120 kVp and 2.5 mm slice thickness. Respiratory traces were 
recorded by the AZ 733V Respiratory Gating SystemTM (Anzai Medical Co. Ltd., Tokyo, 
Japan) system which employed a pressure sensor belt. 4DCT data were binned into 10 equally-
spaced phases across the patient breathing cycle. The total vector target motion was evaluated 
to be less than 1.0 cm across all patients. This total vector motion of 1.0 cm did not require 
further motion mitigation strategies such as abdominal compression per SCCAPTC clinical 
guidelines. Instead, a motion-encompassing treatment strategy was employed that included 
volumetric rescanning (88, 89) of PBS beams to dampen the interplay between scanning 
magnet motion and tumor motion frequencies. 
 
5.2.3 Treatment planning and optimization parameters  
DICOM CT data were imported into the Raystation TPS and PBS beams were optimized for 
dose calculation on the 4DCT phase-averaged image. Treatment plans utilized 1-2 treatment 
fields (2-4 fields with 2x volumetric rescanning) and were planned using single-field robust 
optimization to maintain target coverage under perturbed conditions of 3% range and 3 mm 
setup uncertainty. Prescriptions consisted of proton beam therapy regimens with curative 
intent, ranging from 60-66.6 Gy (RBE) in 1.8-2.0 Gy (RBE) per fraction and using an average 
RBE of 1.1. Additional beam computation settings used for PB and MC optimization included 
default energy layer spacing and spot spacing parameters set to 1.0 cm. A lateral margin of up 
to 1.0 cm was used for spot placement around the target and all optimizations were carried out 




completion of optimization, final MC dose was computed using a sufficient number of ions to 
yield 0.5% statistical uncertainty across the tumor volume. All treatment plans were normalized 
such that the prescribed dose covered 95% of the planning target volumes. 
 
5.2.4 Dosimetric and statistical analysis  
PBS single field optimization was first carried out using PB dose calculation to achieve clinical 
goals for target coverage and dose to OARs in compliance with the current standard of care at 
SCCAPTC. PB-optimized treatment plans were then re-calculated with MC without 
modification to layer spacing, spot spacing or spot intensity distributions. Finally, field-specific 
energy layers, spot positions and spot intensities were reset and re-optimized using MC while 
maintaining the same optimization parameters. Dose differences between the PB-optimized 
(PBopt), MC-recalculated (MCrecalc) and MC-optimized (MCopt) treatment plans were 
recorded for the following plan metrics: CTV V95, CTV homogeneity index (HI), total lung 
V20, total lung VRX (relative volume of lung receiving the prescribed dose or higher), and 
global maximum dose. Pairwise differences in planned dose and dose-volume parameters 
between PBopt, MCrecalc, and MCopt were analyzed using a non-parametric Friedman test. 
 
Perturbed dose distributions were generated in Raystation for the evaluation of plan robustness 
with regard to setup and range uncertainty. Perturbation scenarios were generated by scaling 
CT density by +/- 3% to evaluate the range uncertainty of PBS beams and beam isocenters 
were shifted by +/- 3mm in the x, y and z directions to evaluate patient positioning setup 
uncertainty. For simplicity, this study considered the following two dose perturbation 
scenarios: (+3%, x+3mm, y+3mm, z+3mm) and (-3%, x-3mm, y-3mm, z-3mm). Perturbed 
doses were generated for MC-recalculated and MC-optimized treatment beams and pairwise 
differences between MC-recalculated and MC-optimized perturbed dose distributions were 
evaluated using a non-parametric Wilcoxon sign-rank test. 
 
5.3 Results  
Figure Figure 5.1 illustrates isodose distributions overlaid on a patient planning CT using three 
planned dose conditions: PBopt (A), MCrecalc (B) and MCopt (C). As can be seen in Figure 




posterior beam direction in the MCrecalc dose distribution (B) which causes a reduction in 
proton range. Furthermore, dose shadowing on proton beam paths beyond bone is more 
pronounced in MCrecalc (B) compared to PBopt (A). This under-ranging is corrected in the 
MCopt plan (C), though the distal edge features more lateral dose inhomogeneity than the 
PBopt plan (A). Figure 5.1 (D) shows a DVH for the CTV (green) and lung (blue). There is a 
noticeable drop in dose coverage to the CTV in the MCrecalc plan (dotted line). This dose 
coverage to the CTV is recovered in the MCopt plan (dashed line), while no significant 
differences in lung DVH are observed. Figure 5.1 (E) shows a line dose profile across the center 
of the target for the three treatment plans. While there is reasonable dosimetric agreement at 
the level of the patient midplane, there is lower dose through the tissue/air interface in the 




Figure 5.1. PBS dose distributions for a lung cancer patient using three techniques: clinically approved analytical 
pencil beam (PB) optimization and calculation (A), Monte Carlo (MC) re-calculation of the approved PB-
optimized treatment plan (B) and MC optimized plan (C). Figures A, B and C show the dose distributions (colored 
isodose lines) for each planning technique overlaid on the planning CT and clinical target volume (CTV, green-
filled contour). The bottom left figure (D) show DVH curves for the CTV (green) and lung (blue). Figure D shows 
line dose profiles for each of the three techniques (solid line: PB-optimized, dotted line: MC-recalculation of PB-
optimized plan, dashed line: MC-optimized plan).  
Table 5.1 summarizes dose statistics for the total lung and CTV between the PBopt, MCrecalc 
and MCopt treatment plans. In this 10-patient sample, CTV V95 ranged from 99% to 100% 
with a median of 100% for PBopt plans. For MCrecalc plans, CTV V95 ranged from 77% to 
94% with a median of 90%, a statistically significant drop in target coverage relative to PBopt 




a significant recovery in target coverage (p < 10-5). Overall, MC treatment plans showed a 
reduction of dose homogeneity within the target volume. The median CTV HI (D95/D5) was 
0.98 for PBopt, 0.91 for MCrecalc and 0.95 for MCopt (p < 10-3). Analysis indicated that the 
total lung V20 values were not statistically different among dose calculation and optimization 
scenarios, with median V20 within 2% between PBopt (25%), MCrecalc (25%) and MCopt 
(27%, p = 0.27). Median lung VRX was 7%, 1% and 8% for PBopt, MCrecalc and MCopt plans 
respectively (p <10-3), indicating a reduction in lung volume receiving high dose when 
recalculated with MC. Finally, the global patient max dose increased from a median value of 
106% for PBopt to 109% and 112% for MCrecalc and MCopt, respectively (p < 10-3), using 
fixed levels of MC statistical uncertainty. 
 
 
Table 5.1. CTV V95, CTV homogeneity index (HI), total lung V20, total lung VRX and max point dose for ten 








Median  Range  Median  Range    
CTV D95  ‐6%  [‐9%, ‐2%]  ‐1%  [‐2%, 0%]  0.006 
Global Max Dose  2%  [‐3%, 8%]  1%  [‐3%, 6%]  0.10 
 
Table 5.2. CTV D95 and global max dose under perturbed scenarios of 3% beam over range and ±3mm iso-
center shift in x, y and z.  







 Median Range Median Range Median Range  
CTV V95 100% 99% - 100% 90% 77% - 94% 100% 99%-100% < 10-5 
CTV HI 
(D95/D5) 0.98 0.95 - 1.00 0.91 0.87-0.94 0.95 0.94-0.98 < 10
-3 
Total 
Lung V20 25% 15% - 35% 25% 16% - 34% 27% 20%-37% 0.27 
Total 
Lung VRX 
7% 2% - 11% 1% 0% - 6% 8% 3%-11% < 10-3 
Global 
Max Dose 106% 101% - 113% 109% 
104% - 






Given the inaccuracies of PB dosimetry, as summarized in Table 5.1, robustness evaluation was restricted to 
plans utilizing only MC dose calculation.  
Table 5.2 shows delta values representing the change in CTV D95 and global max dose for 
MCrecalc and MCopt treatment plans under range and setup perturbations: (± 3% density / 
under-range, x ± 3mm, y ± 3mm, z ± 3mm). Median change under perturbation in CTV D95 
was -6% and -1% for MCrecalc and MCopt plans, which presented a statistically significant 
improvement in plan robustness when optimizing with MC (p = 0.006). Change in global 
maximum dose under perturbations was not statistically different between MCrecalc and 
MCopt plans (p = 0.10), indicating that this parameter was most influenced by statistical noise 
in both planning scenarios.  
5.4 Discussion  
In Saini et al. (47) it was demonstrated that analytic algorithms such as PB lack proton dose 
calculation accuracy in highly heterogeneous media typically encountered during lung cancer 
treatments. In another study by Saini et al. (11), PB and MC dose calculation algorithms were 
benchmarked against measurements and it was found that MC provided superior dosimetric 
accuracy, most notably in heterogeneous media. Similarly, Lin et al. (90) benchmarked the 
Eclipse Acuros PTTM (Varian Inc., Palo Alto, CA) dose calculation algorithm. In this clinical 
study, analysis of lung cancer patient treatment plans optimized with a commercial PB 
algorithm and subsequently recalculated with Acuros PTTM demonstrated a median decrease in 
CTV V95 by 10% (90). These results from Lin et al. also agree with recent findings by Taylor 
et al, in which measurements from an anthropomorphic lung phantom concluded that use of 
analytic dose algorithms under-dosed target centers by an average of 7.2% (49). The MC 
planning results presented in this chapter are similar with those of Schuemann et al. (43, 44), 
in which a mean decrease of 11% in tumor control probability of lung cancer from MC 
dosimetry of analytic PB-optimized plans was observed. While these investigations 
summarized the deficiencies in PB algorithms, the impact of MC-based optimization on 
planned dosimetry of lung cancer patients was not addressed. 
While a reduction in target dose was observed when recalculating with MC, CTV coverage 
under MC-based plan optimization was statistically similar to that achieved in the original PB-
based optimization. This illustrates that when changing from PB to MC dose calculation, target 
coverage is lost but can be regained when MC optimization is employed. Similarly, a reduction 
in dose homogeneity between PB-optimized (CTV HI = 0.98) and MC-recalculated plans (CTV 




regained when MC optimization is used (CTV HI = 0.95). These results demonstrate that a 
similar target coverage in lung lesions can be expected when optimizing with PB and MC with 
the caveat of reduced dose homogeneity under MC-based treatment planning/optimization.  
Differences in normal lung tissue dosimetry were less pronounced for large volumes receiving 
low/moderate dose but similar in magnitude for small volumes receiving high dose compared 
to differences in target dosimetry. Total lung V20 remained within a ±2% deviation across the 
three dose calculation techniques, and similar trends were observed for V10 and V5. Dose 
differences in VRX showed a similar trend as CTV coverage across the different dose 
calculation/optimization techniques. Changing from PB to MC-recalculated, VRX was reduced 
from 7% to 1% but increased to 8% under MC- optimization. Regions of high dose in lung 
proximal to targets and tissue interfaces were most affected by differences in the dose 
calculation algorithm. This trend held true for other OARs, though their nominal dosimetry 
was very specific to patient anatomic geometry and tumor size/location. For example, cases in 
which the spinal cord was a dose limiting structure produced large variability in maximum dose 
between PB and MC dose calculation algorithms. 
Analysis of median global maximum dose showed an increase from 106% to 109% for PB-
optimized and MC-recalculated plans respectively, and a further increase to 112% for MC-
optimized plans. It’s worthwhile noting however that MC calculation statistical uncertainty can 
impact maximum point doses. As a fixed statistical uncertainty of 0.5% was used in this study, 
maximum dose may have been decreased further in some cases by further reducing the 
statistical uncertainty setting. Decreasing the statistical uncertainty increases the number of 
simulated ions which improves the precision of MC dose calculation at the expense of increased 
calculation time.  
Interestingly, robustness analysis revealed differences in perturbed dosimetry between the MC-
recalculated and MC-reoptimized treatment plans. Plans that were robustly optimized with PB 
and recalculated with MC had a median change in CTV D95 of -6% under 3%/3mm perturbed 
dose scenarios. In contrast, plans robustly optimized with MC had a negligible median change 
of -1% under 3%/3mm perturbed dose scenarios. These results are relevant for isocentric setup 
perturbations that are orthogonal to an air/tissue/bone interface for any beams directed parallel 
to the interface because under these conditions PB-optimized plans inaccurately estimate lateral 
dosimetry from an infinite slab approximation for each pencil beam and consequently fail to 




uncertainty by accurately estimating lateral spread along the interface from individual particle 
interactions. Unlike target coverage, there was no significant difference in global maximum 
dose between MC-recalculated and MC-optimized plans. This suggests that the effect of the 
robust optimization algorithm was smaller compared to the effect of statistical MC uncertainty 
on point doses.  
The work presented in this chapter provided dosimetric evaluations of MC-based plans for lung 
proton PBS treatments. Further analyses within this study was constrained by several 
limitations. First, the cohort was limited to 10 patients and future work in this area could be 
extended to a larger patient population, including subgroup analysis by disease stage, tumor 
location, magnitude of tumor motion, and beam configuration. Furthermore, while all patients 
in this study received definitive lung cancer proton beam therapy, there was substantial 
variation in the size and location of target volumes across the patient cohort. The large variation 
in target size and location resulted in a high degree of variability in dose to OARs across the 
patients. For this reason, critical OARs exhibiting high variability and/or null dose (e.g. heart, 
esophagus, spinal cord and brachial plexus) were excluded from this analysis. Finally, patient 
dose calculation/optimization was performed on the 4DCT average and not on any of the 
individual respiratory phases which could result in variations to the reported results. Future 
work integrating MC robust optimization under perturbation of intra-fraction tumor motion, by 
calculating 4D MC dose distributions (91) on 4DCT phases while accounting for PBS 
respiratory-synchronized delivery timing, could prove valuable in improving lung proton 
therapy safety and efficacy. 
 
5.5 Conclusions  
In conclusion, a retrospective analysis of lung cancer patients receiving PBS treatments 
demonstrated deficiencies in target coverage when using PB-based dose 
calculation/optimization. The presented analysis demonstrated that these deficiencies were 
successfully resolved using a MC-based treatment plan design. Robust optimization with MC 
planning had reduced sensitivity to range and setup perturbations compared to robust 
optimization using PB-based dose calculation/optimization. Considering these findings, this 
work advocates for clinicians to consider adoption of MC-based treatment planning of lung 





CHAPTER 6: A MACHINE LEARNING-BASED 
FRAMEWORK FOR DELIVERY ERROR 
PREDICTION IN PROTON PENCIL BEAM 
SCANNING USING IRRADIATION LOG-FILES 
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6.1 Introduction 
During PBS irradiation, scanning magnets, ionization chambers and various other components 
precisely steer beam spots to irradiate the target volume while minimizing dose to healthy 
tissue. Although these beam-line components are calibrated to ensure accurate beam 
positioning and intensity, delivery errors in spot positions and intensity (i.e. MU) can 
accumulate, resulting in changes to the delivered dose distributions within patients.  
Various studies have demonstrated the successful use of PBS irradiation log-files for 
reconstruction of delivered dose within patient anatomy (92, 93). In a study by Meier et al. 
validation of an in-house software used for reconstruction of delivered dose distributions 
utilizing PBS log-file data was investigated. In another study Zhu et al. used log-file data for 
PBS patient-specific QA measurements (93). Scandurra et al. demonstrated the successful use 
of log-file-recorded spot parameters to reconstruct dose distributions on clinical patient CT 
scans and reported a mean gamma pass rate of 96.4% between nominal and reconstructed dose 




delivered spot parameters from log-files to quantify and assess the dosimetric effect of delivery 
error of PBS beams on patient treatments (95, 96). Li et al. investigated differences between 
planned and recorded spot parameters by analysing PBS irradiation log-file data across 14 
patient treatments and found standard deviation values of 0.26 mm and 0.42 mm for x and y 
spot positional delivery errors respectively (95). Finally, Belosi et al. (96) found that large dose 
deviations are possible for highly modulated proton PBS plans thus systematic delivery errors 
are important to consider for such cases during treatment planning. 
Although log-file data allows for off-line review of PBS delivery error during patient 
treatments, it is ideal to predict this error up-front during the planning phase. Predicting PBS 
delivery error prior to treatment enables the planner to introduce mitigation strategies that can 
minimize the effect of this uncertainty. These errors in proton PBS are analogous to multi-leaf 
collimator (MLC) positioning errors in photon IMRT and VMAT delivery in which differences 
between planned and delivered MLC positions and MU can result in changes to delivered dose 
distributions within patient anatomy. As discussed in Chapter 2, multiple studies have 
investigated the use of machine/deep learning algorithms to predict delivery uncertainties in 
IMRT and VMAT delivery (65, 68, 97, 98). Carlson et al. demonstrated the use of ML models 
to accurately predict MLC leaf position errors in VMAT treatment plans (65) and showed 
improved gamma pass rates of measured vs. calculated profiles by incorporating the predictions 
into the TPS-calculated profiles. Valdes et al. reported use of an analytical model to accurately 
predict gamma pass rates (measured vs. TPS) of IMRT treatments based on various plan 
complexity parameters including MU, MLC leaf positions and machine type (68). Tomori et 
al. leveraged a CNN to accurately predict patient specific QA gamma pass rate values for 
prostate treatments based on PTV/OAR volume and MU parameters (97).  
While these studies have focused on prediction of delivery error for LINAC-based treatments, 
the utilization of ML for predicting delivery error in proton PBS has not been investigated. The 
aim of this chapter is to investigate the use of ML for prediction of delivery error of PBS beam 
spots using an irradiation log-file dataset generated from a cohort of previously-treated prostate 
patients. The multitude of recorded spot parameters extracted from the log-files allows for the 
training of an ML model that can infer both linear and non-linear relationships between plan 
parameters and log-file-derived delivery errors. In addition to demonstrating the feasibility of 
using ML to predict delivery error in PBS, this chapter also presents a framework for delivery 




chapter, this framework can be used to evaluate dosimetric effects of PBS delivery error prior 
to treatment, during the planning phase.  
 
6.2 Methods 
6.2.1 PBS treatment plans 
A retrospective patient dataset of 20 PBS prostate plans were selected from the clinical TPS 
database at SCCAPTC. The set of treatment plans consisted of 7 low risk (prostate only), 11 
intermediate risk (prostate and seminal vesicles) and 2 high-risk prostate (prostate, seminal 
vesicles and pelvic nodes) targets. All prostate patients were positioned FFS and treatment 
planning was carried out using a lateral (left and right) beam arrangement.  Low-risk prostate 
target volumes were treated with one field per day and utilized a total of two beams to treat the 
PTV to a dose level of 7920 cGy across 44 treatment fractions. Intermediate-risk prostate 
patients were also treated with one field per day and used a total of four beams for treatment in 
which beams 1 and 2 were used to treat the prostate and seminal vesicles to an initial dose of 
5040 cGy in 28 treatment fractions while beams 3 and 4 treated the prostate to a total dose of 
7920 cGy in 16 fractions. High-risk prostate target volumes were treated with 2 fields per day 
and used a total of 4 beams per treatment with beams 1 and 2 treating the prostate, seminal 
vesicles and pelvic nodes to total dose of 5040 cGy in 28 treatment fractions while beams 3 
and 4 boosted the prostate to total dose of 7920 cGy in 16 treatment fractions.  
For this work, all treatments were planned using the Raystation TPS utilizing PB dose 
calculation. All plans were calculated on patient CT datasets using an isotropic dose calculation 
grid size of 3 mm. Treatment fields were optimized using an initial spot placement target 
margin of 0.8 cm around the PTV as well as variable energy layer and inter spot-spacing 
parameters relative to the Bragg peak width and spot size, respectively (energy spacing = 0.8 
cm, spot spacing = 0.8 cm). Optimization objectives were adjusted such that each beam was 
optimized to deliver a uniform dose distribution across the PTV. In total, the planning data set 
consisted of 66 beams and 123,079 PBS beam spots ranging in energy from 132.6 MeV to 
219.2 MeV.  
6.2.2 Assessment of PBS delivery error 
For each patient treatment beam, planned spot positions and MU were extracted from DICOM-




Following treatment, irradiation log-files were extracted from the proton delivery system. 
Recorded spot positions and MU were extracted from the log-files using REGGUI, a 
MATLAB-based software package that supports analysis of PBS irradiation log-files for PBS 
beams delivered with the IBA system (99). Validation of the REGGUI log-file analysis 
functionality has been carried out using a 2d-scintillator detector by Toscano et al. (100). Each 
set of planned spot parameters (i.e. spot position, MU and energy) extracted from the DICOM-
RT files was matched to the corresponding set of delivered spot parameters extracted from the 
log files. Spot parameters were compiled into a centralized dataframe where each row 
contained planned and delivered spot parameters (i.e. x/y position and MU) for each given spot. 
This collection of planned and delivered spot parameters formed the primary dataset which was 
used to quantify spot positional and MU delivery errors. 
Next, the effect of PBS delivery errors on a dose distribution within patient anatomy was 
investigated. This was carried out by first extracting delivered spot positions and MU from two 
fractions of a previously-treated prostate treatment. This test patient had a low-risk prostate 
target and was previously treated using the corresponding treatment schema as described in 
section 6.2.1. Delivered spot parameters from this patient were extracted from irradiation log-
files and inserted into a DICOM-RT file which was imported into the TPS and the 
corresponding dose distribution was calculated on the patient CT using PB dose calculation. 
Target/OAR DVH curves and corresponding dose distributions were evaluated on the original 
and delivered plan.  
6.2.3 Machine learning model training and validation 
In this work three ML model types were selected for use: 1) linear regression, 2) random forest 
and 3) neural network. Training/tuning/testing of these ML models was carried out in the 
following manner: First, the primary dataset consisting of planned/delivered spot parameters 
was randomly split into two separate data sub-sets used for (1) training and (2) testing where 
80% of the data was used for the training set and 20% was reserved for the testing set. During 
this random split, planned/delivered spot parameters were randomly extracted from the primary 
dataset such that the training and test datasets contained a stratified mixture of spot parameters 
across all patients used in this study. In the training dataset, features and targets were defined 
and each ML model was trained to predict spot parameter targets (i.e. delivered spot positions 
and MU) based on spot parameter features (i.e. planned spot positions and MU) as illustrated 





Figure 6.1. Diagram showing the feature and target variables used for training of ML models (a) and workflow 
of model tuning/training/testing (b). 
Model hyper-parameter tuning was carried using 5-fold cross validation with MAE as the 
model evaluation metric. Upon each iteration of hyper-parameter tuning, various combinations 
of model settings were varied and then used for cross validation. This process was repeated for 
multiple iterations for the random forest and neural network model until the MAE was 
minimized. The trained model using the optimal combination of hyper-parameter settings 
yielding the lowest MAE values was then used as the basis for model selection between the 
different machine learning algorithms. Table 6.1 shows the different combinations of hyper-
parameter settings used during cross validation of the random forest and neural network 
models.  
 
Table 6.1. Hyper-parameter settings used during tuning of the random forest and neural network models.  
Note that the linear regression model used in this study only fits linear regression coefficients 
and did not contain any hyper-parameters to tune. Therefore, in the case of the linear regression 




parameter tuning, model selection was carried out again using MAE as the evaluation metric. 
Next, the selected trained model was used to make predictions on the testing data set and the 
resulting MAE was reported. To verify the model was not over-fitting the training data, MAE 
was reported for both predictions made on the training and testing datasets.  
6.2.4 Machine learning models 
ML models used in this chapter were implemented in the python programming language using 
the Scikit-Learn machine learning library version 0.22.2 (101). The following three sections 
briefly describe the ML models used in this study as well as final hyper-parameters selected 
following model tuning.  
6.2.5 Linear regression model 
The linear regression model is a supervised ML model that utilizes ordinary least squares 
regression as described in Ari et. al. and Saunders et. al. (102, 103). The function in Scikit-
learn known as LinearRegression was used to fit a linear model to minimize the residual sum 
of squares between targets within the spot parameters dataset and the spot parameters predicted 
by linear approximation.  
6.2.6 Random forest model 
The random forest model implemented in this chapter is a random forest regression model and 
is primarily based on algorithms described in Breiman and Geurts et al. (66, 104). In the 
implementation of this model, data is first divided into numerous sub-samples. For each 
subsample, the features are used to build a decision tree and this process is repeated until a 
decision tree is constructed for each sub-sample resulting in collection of trees referred to as a 
forest. To make predictions, testing data elements are iteratively ran through decision trees 
within the forest. Prediction values are calculated by averaging the output of all decision trees. 
In this work, 100 sub-samples were generated resulting in 100 decision trees that were built 
using 4 features at each split. These four features were spot position (x any y), MU and energy. 
Other hyper-parameter settings included use of bootstrapping meaning that each decision tree 





6.2.7 Neural network model 
The neural network model implemented in this chapter is described in Murtagh et al. (105). 
This model utilizes an algorithm known as a multilayer perceptron (MLP) which is a class of 
neural networks. The MLP used in this work consisted of three layers where each layer is 
composed of a set of binary classifiers known as perceptrons. The first layer, known as the 
input layer, consists of a set of neurons that represent the input features. In this study, four 
neurons were used in this layer, one for each feature: planned spot positions (x any ), MU and 
energy extracted from the DICOM-RT files. The second layer, known as the hidden layer, 
consisted of a set of neurons that transform values from the input layer using a non-linear 
activation function. Here the hidden layer consisted of 100 neurons using the rectified linear 
activation function for non-linear weighting of neuron inputs. The final layer known as the 
output layer receives values from the hidden layer and transforms them into output values. 
Through the method of backprojection (106), neuron weights throughout each layer are 
iteratively optimized using Adam, an adapted stochastic gradient-based optimization technique 
which is described in Kingma et al. (107). The max number of iterations for optimization of 
neuron weights was set to 200 using a regulariztion term of 0.0001 to prevent overfitting of the 
training dataset. Just as the random forest and linear regression models, the final output of the 
neural network model were predicted delivery values of spot position and MU.  
6.2.8 Prediction of delivered dose distribution on patient anatomy 
A previously-treated prostate plan and corresponding log-file delivery record was selected to 
quantify the prediction accuracy of the ML model with the best prediction accuracy. This 
prostate plan was not included in the training data set to ensure unbiased verification of our 
trained model. The treatment plan was used as an input to the trained ML model to obtain 
predicted spot parameters. Finally, these predicted spot parameters were used to create a TPS-
compatible DICOM-RT file that was imported into the Raystation TPS to generate a predicted 
dose distribution. Furthermore, log-file parameters of the delivery of two fractions of the plan 
were used to extract delivered spot parameters. Like predicted spot parameters, the delivered 
spot parameters were inserted into a DICOM-RT file so that log-file-delivered dose distribution 
could be calculated on the patient’s CT within the TPS. The result was a three-way dose 
comparison between (1) original treatment plan, (2) predicted delivery, and (3) log-file-






6.3.1 Assessment of PBS spot delivery error 
The spot positional delivery error was analyzed using histogram plots where each bin is the 
difference between the planned spot positions and delivered spot positions extracted from the 
log-files. Applying a Gaussian fit to this data yielded standard deviation values of 0.39 mm and 
0.44 mm and mean values of -0.1 mm and 0 mm for the x and y positional delivery errors 
respectively as shown in Figure 6.2.  
 
 
Figure 6.2. Gaussian fit of histogram plots with respective standard deviation (σ) and mean (µ) values for x and 
y positional delivery error between delivered and planned spot parameters. 
A similar histogram of the MU delivery error was generated where each bin is now the 
percentage error between planned and delivered MU for each spot in the training dataset. 
Results show a non-normal distribution that is biased towards the positive x-direction as can 





Figure 6.3. Histogram plot of the percent error of MU delivery between planned and delivered beam spots.  
To demonstrate the effects of delivery errors on dose distributions within patient anatomy, 
delivered spot parameters from a log-file were used for dose calculation on a low-risk prostate 
patient CT. Calculated dose distributions of the original treatment plan (Plan) and delivered 
plan calculated with spot parameters extracted from the corresponding log-file (Plan-Logs) are 
shown in Figure 6.4.   
 
 
Figure 6.4. Dose distributions in color wash of Plan (a) and Plan-Logs (b) with the prostate PTV (red contour). 
Here Plan refers to the nominal plan and Plan-Logs refers to the dose reconstruction using log-file data.  
As can be seen in Figure 6.4, dose differences between Plan and Plan-Logs are most significant 
at higher iso-dose levels, inside and near the PTV. Figure 6.5 shows a dose difference between 
the Plan and Plan-Logs which allows for better visualization of the differences between these 
two plans.  
 
 




6.3.2 Model selection  
 
Figure 6.6 shows a bar plot of MAE for the prediction of spot positions (x and y coordinates) 
and MU using the trained linear regression, random forest and neural network ML models. 
 
 
Figure 6.6. Bar plot showing MAE for the prediction of x-spot position, y-spot position and spot MU across three ML 
models: random forest, neural network and linear regression.  
As mentioned in Section 6.2.3, MAE values were calculated during cross validation of the 
training dataset. Cross validation of the trained random forest model resulted in MAE values 
of 0.15 mm, 0.13 mm and 0.01 MU for prediction of x-spot positions, y-spot positions and spot 
MUs respectively. Cross validation of the neural network model resulted in MAE values of 
0.33 mm, 0.70 mm and 0.02 MU for prediction of x-spot positions, y-spot positions and spot 
MUs respectively. Finally, cross validation of the linear regression model resulted in MAE 
values of 0.33 mm, 0.68 mm and 0.01 MU for prediction of x-spot positions, y-spot positions 
and spot MUs respectively. As shown in Figure 6.6, the random forest model had the lowest 
MAE for prediction of spot x and y positions. Compared to the linear regression model the 
random forest model had slightly larger MAE for prediction of MU however. Despite this fact, 
this study choose to implement the random forest model as another study (100) has reported 
that delivery errors in spot position have a much more significant impact on treatment plan 
quality than MU delivery errors.  
6.3.3 Random forest model evaluation 
Further quantification of the prediction accuracy of the trained random forest model is 




where each bin is the difference between log-file-recorded position and predicted position 
using the trained random forest model on the testing dataset.   
 
 
Figure 6.7. Histogram plot of the difference between random-forest-predicted and log-file-recorded x and y spot 
positions with associated Gaussian curves using the test dataset.  
As shown in Figure 6.7, the Gaussian curve fit to the positional error bins had standard 
deviation values of 0.22 mm and 0.11 mm and mean values of 0 mm for the x and y positional 
prediction errors respectively. 
To ensure model over-fitting was not occurring, MAE prediction values were analyzed for 
model predictions of spot parameters using the training and testing datasets. Figure 6.8 
compares the MAE of the random forest model predictions of spot parameters using training 
and testing data.  
 
 





As seen in Figure 6.8, compared to the training dataset a slight decrease in MAE when 
performing predictions on the testing dataset was observed. The percent difference in MAE for 
spot parameter prediction was -10.2%, -12.3% and -3.2% for x-spot position, y-spot position 
and MU respectively. Because MAE of the random forest model predictions was slightly lower 
for the testing dataset than the training dataset, it was concluded that the random forest model 
was not over-fitting the data and was effective in making predictions on unseen data.  
Next, a three-way comparison of dose distributions and DVH data was evaluated for Plan, Plan-
Logs and the plan predicted by the random forest model (Plan-RF). Figure 6.9 shows the three 
plans for the same example patient that was presented in Figure 6.4. 
 
 
Figure 6.9. Three-way comparison of dose distributions for Plan (a) Plan-Logs (b) and Plan-RF (c) with the PTV 
target volume contoured in red.  
As can be seen in Figure 6.9, visual differences in the dose distribution between Plan and Plan-
Logs are more substantial than differences between Plan-Logs and Plan-RF indicating that the 
random forest model can effectively predict delivered dose distributions. Figure 6.10 shows 






Figure 6.10. DVH curves for the PTV and several relevant OARs corresponding to Plan, Plan-Logs and Plan-
RF.  
As can be seen in Figure Figure 6.10, DVH curves for Plan, Plan-Logs and Plan-RF are very 
similar for OARs (i.e. the bladder, rectum and right femoral head) which are primarily located 
in low-dose regions within the patient anatomy. In contrast, more prominent differences can be 
observed in the DVH curve for the PTV. As shown in Figure 6.10, reduction in prescription 
iso-dose coverage is observed when comparing the Plan to Plan-Logs. Comparison of DVH 
curves demonstrates that this loss in prescription iso-dose coverage is accurately predicted by 
the trained random forest model. 
6.4 Discussion 
In this study delivery error of a fixed IBA PBS beam-line was characterized by comparing 
planned spot parameters extracted from DICOM-RT files to the delivered parameters extracted 
from the corresponding irradiation log-files. As presented in Figure 6.2 the resulting x and y 
positional delivery errors were calculated to be 0.39 mm and 0.44 mm respectively. Similar 
analysis of spot positional delivery error was studied by Toscano et al. and Li et al. (95, 100). 
In the paper by Toscano et al. PBS delivery error of an IBA beam-line was investigated using 
standardized spot patterns and corresponding log-files which were extracted following beam 
delivery. The reported standard deviation values for spot positional accuracy in this work were 
0.57 mm and 0.58 mm for the x and y positions respectively (100). In the other study by Li et 




Japan) was studied using log-file data across 14 patient treatments. The reported standard 
deviation values for positional PBS beam spot delivery errors in this work were 0.26 mm and 
0.42 mm for x and y respectively (95).  
Compared to the work presented in this chapter, the positional delivery errors reported by 
Toscano et al. are slightly larger than the values reported in this work which can be attributed 
to multiple variables. First, Toscano et al. analyzed standardized spot patterns which spanned 
across a larger field size and range of energies whereas the field sizes presented in this chapter 
were smaller and limited to energy ranges used for the treatment of prostate targets. Future 
work can expand to multiple disease sites which would utilize larger field sizes and more 
variable energy ranges. Other discrepancies between this study and that reported by Toscano 
et al. and Li et al. could be attributed to differences in machine type and technique. In this work, 
log-files were analyzed from a fixed PBS beam-line whereas Toscano et al. used log-file data 
from a rotational gantry across various beam angles and Li et al. utilized completely different 
proton therapy vendor/beam delivery system.  
Various studies have demonstrated the use of ML models for the prediction of MLC leaf 
positioning and MU errors and the resulting effect on dose distributions within patient anatomy 
for IMRT and VMAT treatments (65, 68, 97, 98) as discussed in Chapter 2. Like IMRT and 
VMAT, the work presented in this chapter demonstrates that delivery errors in PBS proton 
therapy can impact dose distributions within patient anatomy. PBS log-files comprise a wealth 
of beam delivery data allowing for accurate characterization of PBS delivery errors. The large 
amounts of beam data in log-files is suitable for effective training/testing/tuning of ML models 
for the prediction of PBS delivery errors. This work has demonstrated the novel use of ML 
algorithms to predict delivered PBS spot parameters using irradiation log-file data as a training 
dataset. Dose distributions generated by the presented random forest model were evaluated on 
patient anatomy. Isodose distributions and DVH data between the approved plan and log-file 
delivery show a reduction in prescription isodose coverage for a test prostate PTV while good 
agreement was observed between the log-file delivery and predicted dose distributions using 
the trained random forest model. 
When interpreting differences in dose distributions between the approved plan and 
reconstructed log-file plan it is also important to consider any uncertainties associated with the 
recording of spot parameters to the log-files. In the study by Toscano et al. it was reported that 




attributed to uncertainties inherent to the log-file data (100). These log-file uncertainties arise 
from a limitation of the beam-line ionization chambers for the measurement of delivered PBS 
beam spot positions. The beam-line ion chambers rely on vertical and horizontal wire strips of 
limited spatial resolution and determination of spot positions across these strips requires 
interpolation of a three-point-based Gaussian fit which can result in uncertainties of the same 
order of magnitude as the delivery errors calculated from the log-file data (100). To account 
for this uncertainty, Toscano et al. benchmarked log-file-derived spot parameters against 
measurements. This data was used to characterize the random and systematic components of 
log-file uncertainties and a lookup table to correct for these errors was generated. Future work 
will include a similar benchmarking of the log-file data presented in this work against 
measurements to characterize associated uncertainties in predicting delivered dose distributions 
using the trained random forest model.  
This work presented in this chapter had the following limitations. First, the predicted dose 
distribution was evaluated on only a single prostate patient using only 2 fractions of log-file 
delivery data. Additional future work can expand to evaluate ML model accuracy on a broader 
set of patients and disease sites utilizing a comprehensive set of log-files across all delivered 
treatment fractions. Analysis of PBS log-file data across all fraction deliveries will allow for 
enhanced quantification of the effect of delivery errors on dose distributions within patient 
anatomy. Finally, utilization of a trained ML model enables the possibility to mitigate the dose 
degradation caused by PBS delivery error. One mitigation strategy could be to intentionally 
introduce small perturbations in the planned PBS spot parameters based on predicted 
parameters to proactively correct for this delivery error. Such an application of a trained ML 
model would also serve as basis for future studies of this topic.  
6.5 Conclusion 
This study demonstrated the use of an ML model to accurately predict delivered PBS spot 
positions and MU using information from irradiation log-files as part of a training dataset. Log-
file data along with treatment planning data from DICOM-RT files across 20 PBS patient plans 
was used to train three different types of ML models to predict delivered PBS spot parameters 
based on planned parameters. Validation results show that the random forest model had the 
lowest MAE compared to the neural network and linear regression models for prediction of the 
delivered PBS spot parameters. Finally, a scripting framework was developed to 1) reconstruct 




irradiation log-files and 2) calculate a dose distribution using the predicted spot parameters as 
generated from the ML model. Analysis of dose distributions and DVH data for a prostate 
patient indicate that the trained random forest model was effective in accurately predicting the 
delivered dose distributions within patient anatomy for a prostate patient using limited number 









CHAPTER 7: CONCLUSIONS 
7.1 Summary 
This thesis has explored various methods in which to improve PBS delivery for the treatment 
of cancer. The research carried out in this thesis has been conducted at the Seattle Cancer Care 
Alliance Proton Therapy Center along with the support of the University of Wollongong, 
Centre for Medical Radiation Physics. Furthermore, the work conducted in this thesis has 
served as the basis of clinical implementation of various PBS treatment techniques aimed at 
improving PBS beam delivery at SCCAPTC. It is the intention of this thesis that the presented 
work can be used as the basis for clinical implementation of similar technology and techniques 
in other proton therapy clinics. The following sections re-visit the specific aims that were 
presented in chapter section 1.2 and summarize key findings and conclusions of Chapters 3 - 
6.  
Aim 1: Investigation and implementation of aperture collimators for PBS 
Chapter 3 investigated the use of aperture collimators for PBS treatments to sharpen lateral 
penumbra. This work was motivated by the fact that penumbra sharpening of PBS beams can 
result in a reduction of dose to critical OARs adjacent to the PTV for certain disease sites. The 
work presented in this chapter was published in journal of Biomedical Physics & Engineering 
Express and was the first to comprehensively characterize penumbra reduction (i.e. difference 
in lateral penumbra with and without collimation) of collimated PBS beams as function of 
relevant treatment planning parameters including airgap, range shifter thickness and beam 
energy. Characterization of PBS lateral penumbra reduction included derivation of analytical 
equations to fit the TPS-calculated penumbra reduction as a function of air gap and depth for 
various range shifter thicknesses. Data analysis revealed that use of collimators for PBS beams 
has the largest effect at shallow depths when using small airgaps. Penumbra reduction was 2.7 
mm, 3.7 mm and 4.2 mm for RS0, RS45 and RS75 respectively. At deeper depths, penumbra 
reduction was reduced to 1 mm at a depth of approximately 23 cm for RS0 and 20 cm for RS40 
and RS75. Next, a clinical test brain patient was used to compare lateral penumbra with and 
without use of PBS aperture collimation. Dosimetric analysis of the treatment plan for this test 
patient showed enhanced lateral penumbra sharpening which was in good agreement with the 
previously-presented analytical equation as well as enhanced OAR sparing for critical OARs 
adjacent to the target. Finally, all TPS-calculated penumbra values were validated against film 




beams was accurate and acceptable for clinical use using the Raystation MC dose calculation 
algorithm. 
Aim 2: Clinical validation of PBS treatments in the seated position 
In Chapter 4, a commercial TPS implementation of a treatment chair for a fixed proton 
beamline was validated. This work was published in Physica Medica and was the first to 
present a comprehensive validation of the treatment chair implementation within the Raystation 
TPS known as the 6D couch. Validation of the chair pitch and roll capabilities within 
Raystation was performed through creation of phantom plans that compared (1) TPS-generated 
DRRs with planar x-rays in the treatment room and (2) TPS-calculated dose profiles against 
ion chamber array measurements. The DRRs were found to have an acceptable agreement with 
planar x-rays based on visual inspection and for the dose map comparison between measured 
and calculated, gamma index analysis for all measured beams was >95% at a 3% dose-
difference and 3 mm distance-to-agreement tolerances. Finally, for end-to-end testing, an 
anthropomorphic phantom was successfully setup at isocenter in the seated position and a 
treatment was delivered. These measurements concluded that the Raystation treatment chair 
features were consistent with IEC 61712 standards are suitable for clinical treatments. 
Validation of this treatment chair within the TPS will allow for its use in a fixed proton PBS 
beamline at SCCAPTC.  
Aim 3: Comparisons of PB and MC dose calculation in lung 
Comparisons between MC and PB dose calculation for lung treatments was investigated in 
Chapter 5. To highlight the dosimetric impact on treatment planning between these two dose 
calculation algorithms, a comparative dosimetric analysis between MC and PB was performed 
on ten lung patient plans using the Raystation TPS. Across this patient dataset, sample dose 
differences between PB-optimized, MC-recalculated, and MC-optimized plans were recorded 
for the CTV and several OARs for the nominal as well as perturbed dose scenarios to assess 
the impact on robustness. Across the ten-patient sample, it was found that CTV V95 decreased 
significantly from 99–100% for PB-optimized to 77–94% for MC-recalculated and recovered 
to 99–100% for MC-optimized. This means that the use of PB dose calculation for lung 
treatments can result in significant under-dosing of the target volume. As mentioned previously 
in Chapters 2 and 5, Raystation’s MC dose calculation has been shown to have a high level of 
accuracy within patient anatomy across a multitude of disease sites. Resultingly then, this work 




of lung lesions as well as other disease sites within highly heterogenous media to ensure 
accurate dosimetry.  
Aim 4: Application of machine learning for prediction of PBS delivery error 
A machine learning framework for PBS delivery error prediction using irradiation log-file data 
was explored in Chapter 6. In this work, PBS log-file data was extracted from a set of 20 
prostate patient treatment deliveries. Delivered spot parameters (i.e. x-y position and MU) as 
recorded in the log-files was compared against planned parameters to analyze the magnitude 
of the delivery error of PBS beams. This analysis revealed that positional errors were Gaussian 
in shape with standard deviations of 0.39 mm and 0.44 mm for the x and y positional delivery 
errors respectively. The log-file and treatment planning data across the 20-patient sample was 
used to train/test 3 ML models to predict the delivery error of PBS beams. Model testing 
showed that the random forest regression model had the best performance for delivery error 
prediction and was able to predict positional uncertainty to within a standard deviation 0.22 
mm and 0.11 mm for x and y positions respectively. The random forest model was then used 
as the basis of a scripting framework that allowed for generation of log-file-delivered as well 
as ML-predicted dose distributions within the Raystation TPS for patient treatment plans. 
Analysis of DVH data as well as dose distributions showed good agreement between the ML-
predicted dose and log-file-delivered dose distribution. While the topic of delivery error 
prediction using ML has been investigated for IMRT and VMAT delivery (see Section 2.4) the 
published work presented in this chapter was the first to apply ML for the prediction of PBS 
delivery error. The delivery error prediction framework presented here opens to door to the 
possibility of pre-treatment review of dosimetric effects of PBS delivery error within a TPS 
using predictive analytics.  
7.2 Future Work 
The work presented in this thesis builds a foundation for numerous future studies that address 
novel improvements in PBS proton therapy. On the topic of using aperture collimators for PBS 
delivery, the methodology presented in this thesis can be applied to the characterization of 
lateral penumbra across different proton therapy vendors/systems. Future work on this topic 
also includes further validation of the analytical equation for penumbra reduction as presented 
in Chapter 3 which was tested against results from a single patient plan. Validation of the 
analytical penumbra equation across multiple patients/disease sites would ensure the suitability 




PBS apertures. This knowledge can assist clinicians in making the decision of whether to use 
apertures during the treatment planning phase.  
The work carried out in Chapter 4 validates the clinical implementation of chair-based proton 
therapy within the Raystation TPS allowing more flexibility in treatment planning on a fixed 
beamline. Future work on this topic, currently underway, is to use Raystation’s chair model to 
explore the feasibility of treating ocular melanoma patients on a fixed PBS beamline at 
SCCAPTC. The increased flexibility of chair-based treatment planning will also enable 
treatments of disease sites not normally treated on a fixed PBS beamline which can be the basis 
of future studies.    
The work carried out in Chapter 4 can be extended to further explore the impact of PB vs MC 
dosimetry on complex disease sites beyond lung. Other future work on this topic relates to 
improving on the dose calculation time when using a commercial MC dose engine. Recent 
implementations of commercial MC dose engines are highly optimized and computation time 
is much less compared to traditional MC codes used for proton beam transport (e.g. GEANT4 
(108) ). Despite this reduced computation time, dose calculation/optimization for large fields 
in highly heterogenous media can be significantly longer for MC compared to PB-based 
treatment planning. Recently Raysearch Laboratories has released Raystation version 10A 
which supports GPU-based dose calculation for the MC dose engine. Various studies have 
shown significantly decreased MC calculation when using a GPU (109, 110). Future studies 
will include validation of Raystation’s GPU-based MC dose engine as well as benchmarking 
of calculation times.   
Finally, on the topic of machine learning there are numerous future applications for improving 
PBS treatments. One such study that is highly relevant to this thesis is to expand the prediction 
of PBS delivery error to a proton beam delivery system that utilizes active aperture collimation. 
One such implementation of this is Mevion’s Adaptive Aperture™ which uses a tertiary proton 
PBS collimation system as described by Grewal et al. (22). In this system, delivery error can 
be present in both PBS beam spot positions as well as aperture movements and analysis of this 
system’s log-files could enable characterization of these delivery errors and correspondingly a 
predicted ML-based framework like the one presented in Chapter 6 could be created for such 
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